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GENERAL INTRODUCTION 
 
1.1. ENROFLOXACIN, A FLUOROQUINOLONE ANTIMICROBIAL COMPOUND 
  
1.1.1. General considerations of enrofloxacin use in turkeys 
In modern poultry industry, turkeys have been selected for growth rate and feed 
efficiency rather than for robustness and resistance to disease. Disease outbreaks often lead to 
extensive carcass condemnations at processing, resulting in significant economic losses. To 
minimize these economic losses due to microbial disease, therapeutic programs are needed 
using agents that have the ability to rapidly kill any bacterial pathogen that invades the poultry 
flocks (Tanner, 2000). Other important matters to consider are the cost-to-benefit ratio of the 
treatment, the available administration route, the drug withdrawal time, and the antimicrobial 
susceptibility of the target pathogen (Tanner, 2000). 
After flumequine, enrofloxacin was the second antimicrobial fluoroquinolone compound used 
in veterinary medicine. The drug is active against pathogenic bacteria that play a significant 
role in turkey respiratory disease or septicaemia: Mycoplasma sp., Avibacterium 
paragallinarum, Pasteurella sp., Escherichia coli, Staphylococcus sp. and Erysipelotrix 
rhusiopathiae. The current treatment schedule advises administration of enrofloxacin at a 
dose of 10 mg/kg body weight for 3 to 5 continuous days.  When mixed bacterial infections 
are involved treatment should last for 5 continuous days. After such treatment several clinical 
trials have observed a rapid decrease in mortality, clinical symptoms and respiratory tract 
lesions. In most cases, a complete eradication of the causative bacterial organism was reported 
(Braunius, 1987; Behr et al., 1988; Hafez et al., 1992; Cargill, 1995; Gautrais and Copeland, 
1997; Marien et al., 2007). When involved in the infection, complete eradication of 
Mycoplasma sp. was not accomplished, but enrofloxacin treatment reduced the mycoplasma 
excretion and mortality rates (Hinz and Rottmann, 1990; Rainhardt et al., 2005). 
Enrofloxacin can be administered through drinking water. This route of administration proves 
most effective in clinical outbreaks of microbial disease (Tanner, 2000). Advantages of water 
medication are the rapid response, medication reaching the birds within short time and 
convenience of administration. Possible disadvantages are that impurities in the water (bi- or 
trivalent cations) may reduce absorption. The acrid taste of enrofloxacin which may 
contribute to variations in water consumption in pigs, does not affect the water palatability in 
poultry. Parenteral injection delivers a correct dose but is labour-intensive and results in 
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considerable stress in the birds. Feed incorporation of antimicrobials for therapeutic purpose 
is less effective because of the time to manufacture, the inappetence and the inability to 
compete for feed in sick animals. Antimicrobial sensitivity testing should be conducted to 
support the antimicrobial treatment and should be repeated if no clinical improvement is 
noticed after two or three days of treatment. 
 
1.1.2.  Structure/activity relationships and physicochemical properties of enrofloxacin  
Enrofloxacin is a fluoroquinolone antimicrobial drug derived from nalidixic acid. Like 
all quinolones, it is manufactured synthetically. Nalidixic acid, discovered in 1962, was the 
first clinically approved 4-quinolone-type compound, but had several limitations. The drug 
showed only modest activity against Gram-negative bacteria, restricted to the 
Enterobacteriaceae, and possessed poor pharmacokinetic properties regarding absorption and 
distribution. Therefore, nalidixic acid proved only effective against urinary tract infections. In 
addition, the molecule had a tendency to select for resistant organisms and induced several 
toxic effects (Appelbaum and Hunter, 2000; Walker, 2000b; Martinez et al., 2006). Hence, 
several structural modifications have been implemented to the “original” molecule of 
nalidixic acid, to improve its antibacterial activity and its pharmacokinetic features (Chu and 
Fernandes, 1989; Sarkozy, 2001).  
 
 
                                            
 
Figure 1. Structural formulas of nalidixic acid and enrofloxacin (adapted from Sarkozy, 2001). 
 
First, the naphthyridone nucleus (N at position 1 and 8) was transformed into a quinolone 
nucleus, a ring structure containing only one nitrogen in position 1. Halogenating position 6 
of the quinolone nucleus with a fluorine atom substantially broadened the antibacterial 
activity spectrum by improving the clinical activity against Gram-positive bacteria and 
enhanced oral bioavailibility and tissue penetration (Chu and Fernandes; 1989; Sarkozy, 
          Nalidixic acid 
                   Enrofloxacin 
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2001). The introduction of the piperazinyl (a heterocyclic nitrogen-containing ring) side chain 
at position 7 of the quinolone nucleus enhanced activity by increasing the ability of the drug 
to penetrate the bacterial cell wall improving once more activity against Gram-negatives, 
including Pseudomonas sp. (Chu and Fernandes; 1989; Sarkozy, 2001). Adding a 
cyclopropyl-group at position 1 of the nitrogen ring and an etylgroup to the piperazinyl ring 
increased the lipid solubility and the volume of distribution of the compounds (Sarkozy, 
2001) again enhancing potency against members of the family Enterobacteriaceae and 
Pseudomonas aeruginosa (Chu and Fernandes, 1989).  
All these transformations lead to the construction of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-(4-ethyl-1-piperazinyl)-3-quinolone-carboxilic acid, or enrofloxacin, with the following 
physicochemical properties. The dissociation constants of enrofloxacin are pKa1=5.94  and 
pKa2=8.70 corresponding to the carboxylic acid group on the 3- position and to the basic 
piperazynil group in the 7-position, respectively (Lizondo et al., 1997). These constants help 
define the state of ionization of enrofloxacin since the molecule can exist in four possible 
analogues depending on the environmental pH: an acidic cation, a neutral un-ionized species, 
an intermediate zwitterion and a basic ion (Lizondo et al., 1997). Maximal transfer of 
enrofloxacin from the aqueous to the lipid phase occurs at pH 7.0. Below and above this pH, 
partition coefficients (Pc) of the drug decrease (i.e. Pc<3.48) indicating higher polarity and, 
therefore, minor transfer (Lizondo et al., 1997; Martinez et al., 2006). This lipophility of 
enrofloxacin facilitates its diffusion into biological tissues, including bacterial cells. The 
aqueous solubility of enrofloxacin is low between pH 6.0-8.0, which is near its isoelectric 
point. Maximal aqueous solubility (i.e. 10.42 mg/ml) is achieved at pH 5.02. When a 
concentrated acetate buffer is used, the amount of enrofloxacin solubilized can be increased 
(> 100 mg enrofloxacin/ml using a 1.178 M acetate buffer) (Lizondo et al., 1997). According 
to these physicochemical properties with moieties of the molecule being lipophilic and 
lipophobic as well as having different areas of positive and negative charge (zwitterion 
properties) enrofloxacin has the capacity to cross biological membranes easily and achieve 
high concentrations in body tissues. 
 
1.1.3. Bacterial topoisomerases and the mechanisms of enrofloxacin action  
The bacterial chromosome is a continuous, circular, double-stranded DNA molecule 
approximately 1.000 times longer than the bacteria in which it is contained. To fit into the 
cell, the DNA ring must be condensed into a negative supercoil through repeated twisting 
(Walker, 2000b; Hawkey, 2003). Each one of such twists results in one superhelical turn, 
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which can only be released by breaking the covalent bonds of the DNA backbone.  Enzymes 
that catalyze such conversions are called topoisomerases (Messer, 1999; Walker 2000b; 
Hawkey, 2003). Enrofloxacin inhibits the activity of two of those enzymes: DNA gyrase and 
topoisomerase IV (Hawkey, 2003).  
DNA gyrase (or topoisomerase II) is a tetramer of two A and B subunits A2B2, encoded by 
the gyrA and gyrB genes, respectively (Hawkey, 2003; Martinez et al., 2006). The enzyme 
introduces negative supercoils into DNA, which is important for initiation of DNA 
replication, and relieves torsional stress expected to accumulate ahead of transcription and 
replication complexes (Drlica, 1999; Hooper, 2000; Hawkey, 2003). This is obtained by 
wrapping DNA into a positive supercoil and then passing one region of duplex DNA through 
another via DNA breakage and rejoining (Hawkey, 2003). In addition, the enzyme removes 
knots from the DNA and helps bending and folding it (Drlica and Zhao, 1997). DNA gyrase is 
the primary target of enrofloxacin for Gram-negative bacteria (Hawkey, 2003). 
Composed of two C and E subunits and encoded by the parC and parE genes respectively, 
topoisomerase IV is similarly structured as DNA gyrase. Also the reaction mechanism is 
similar to that of DNA gyrase, although topoisomerase IV binds to DNA crossovers rather 
than wrapping DNA. The enzyme is primarily involved in decatenation, the unlinking of 
daughter chromosomes following replication so that segregation into the daughter cells can 
occur (Hawky, 2003). Topoisomerase IV is the primary target of enrofloxacin in Gram-
positive bacteria (Hawkey, 2003).  
Enrofloxacin induces a conformational change in these two topoisomerases which traps them 
on the bacterial DNA as drug/enzyme/DNA-complexes. This prevents religation of the broken 
DNA strands and thus DNA synthesis and cell growth (Drlica, 1999).The bacteriostatic action 
of enrofloxacin is related to this complex formation. The bactericidal action of enrofloxacin, 
however, is thought to be a separate event and three modes of cell killing are suggested 
(Brown and Reeves, 1997; Martinez et al., 2006). 
The first mode involves removal of gyrase-drug complexes from DNA and liberation of lethal 
double strand DNA breaks. This mechanism requires RNA and protein synthesis and is only 
effective against dividing bacteria. The second mode of action postulates that DNA ends are 
released, albeit with the gyrase subunits attached. This mechanism does not require RNA and 
protein synthesis (since it is chloramphenicol insensitive), can act on bacteria that are unable 
to multiply and becomes more prominent as drug concentrations increase. The third mode 
requires RNA and protein synthesis but does not require cell division. This mechanism may 
correlate with trapping of topoisomerase IV complexes on DNA. 
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Some aspects of bactericidal action fail to fit into these schemes. High concentrations of the 
drug (quinolones), for example, are not as effective in killing bacteria as moderate 
concentrations (Drlica and Zhao, 1997). It has been suggested that inhibition of RNA 
synthesis, which occurs at high concentrations might interfere with lethal removal of 
complexes. However, at high concentrations, ciprofloxacin, a metabolite of enrofloxacin, 
predominantly kills by a mode that is not blocked by protein synthesis (Drlica and Zhao, 
1997). A satisfactory explanation for this behaviour has not yet been found and therefore the 
precise mode of action of the drug is not yet completely understood. 
Additionally, enrofloxacin exhibits immunomodulatory effects. In vitro, it stimulates the 
oxidative capacity of phagocytic neutrophils (Hoeben et al., 1997a; 1997b) enhancing their 
phagocytic killing and therefore strengthening the innate host defense. Ciprofloxacin, a 
metabolite of enrofloxacin, downregulates the release of cytokines such as TNFα (Khan et al., 
2000; Purswani et al., 2002) reducing the acute phase response which is a cascade of harmful 
inflammatory reactions caused by exposure to bacterial endotoxin (also known as LPS 
compound of the Gram-negative cell wall, released in the blood stream during bacteraemia or 
in inflammatory tissue). 
 
1.1.4.  Acquired resistance to enrofloxacin  
Acquired resistance to fluoroquinolone antimicrobials, including enrofloxacin, is most 
often chromosomally mediated. The major mechanisms are mutations in the drug targets, 
over-expression of efflux pumps and loss of porins (Brown and Reeves, 1997; Hooper, 2001a, 
2001b; Chen and Lo, 2003). After acquirement the organism passes the resistance mechanism 
vertically to surviving progeny (Robicsek et al., 2006a). 
Mutations in the drug targets are the primary mechanism for enrofloxacin resistance which 
lead to inefficient binding of enrofloxacin to the target enzymes. In Gram-negative bacteria 
(e.g. E. coli) the primary target (for the first step mutations) is the gyrA gene of the DNA 
gyrase (Hooper, 2001a). Mutations in the gyrA gene are located in a small region called the 
quinolone resistance-determining region (QRDR). Two amino acids most commonly 
substituted are Ser83 and Asp87 (Hooper, 2001a). Recently, substitution of the same amino 
acids after mutation in the gyr A gene have been reported in O. rhinotracheale, resulting in 
isolates with reduced susceptibility against enrofloxacin (Marien et al., 2006a). In some 
Gram-positive bacteria (e.g. S. aureus) the primary target is the parC gene of topoisomerase 
IV (Ferrero et al., 1994; Hooper, 2001a). For this parC gene a similar QRDR has been 
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reported. Mutations in the gyrB and parE genes are less common (Chen and Lo, 2003; 
Hooper, 2001a). 
In most bacteria, first step mutations lead to only small (2 to 8) increases in minimal 
inhibitory concentrations (MICs). The organism becomes less susceptible to enrofloxacin, a 
condition that is not clinically detectable. Only after accumulation of additional point 
mutations in different segments of the bacterial genome encoding for the topoisomerases 
resistance is conferred. Single-step mutation frequencies may vary among bacterial species. In 
E. coli the single step mutation frequency is <10-7 (Lindgren et al., 2005), in Mycobacterium 
sp. 10-7 to 10-8 (Sindelar, 2000) and in Chlamydia sp. 10-8 (Rupp et al., 2008). Consequently, 
frequencies at which bacteria develop resistance to a fluoroquinolone compound (i.e. after 
two concurrent, independent target mutations) are low and rated at 10-14 to 10-16 (Drlica, 2003; 
Strahilevitz and Hooper, 2005). Resistance after single step mutations is only seen in 
Campylobacter sp. (Payot et al., 2002) and in species with MICs already high like 
Pseudomonas sp. and Staphylococcus sp. (Brown and Reeves, 1997). However, when 
resistance to one quinolone is acquired, at least some degree of resistance to all the other 
drugs in this group has been observed (Brown and Reeves, 1997). 
Increasing the activity of efflux pumps does not confer but may contribute to resistance to 
fluoroquinolones (Brown and Reeves, 1997; Hooper, 2001a; Chen and Lo, 2003). These 
efflux systems are typically capable of causing resistance to non-structure-related 
antimicrobials and are referred to as multi drug resistant pumps (Hooper, 2001a). Efflux pump 
systems leading to fluoroquinolone resistance identified in Gram-negative bacteria are MexA-
MexB-OprM, MexE-MexF-OprN and MexC-MexD-OprJ in Pasteurella aeruginosa, and 
AcrA-AcrB-TolC and marR–efflux system in E. coli (Hooper, 2001a; Chen and Lo, 2003). 
Efflux pumps in Gram-positive bacteria contributing to fluoroquinolone resistance are NorA 
pumps (Staphylococcus aureus), LfrA efflux pumps (Mycobacterium sp.) and an unidentified 
energy-dependent efflux pump (Enterococcus faecalis and E. faecium) (Hooper, 2001a; Chen 
and Lo, 2003). 
Another way to resistance is achieved by loss of porins, preventing enrofloxacin from 
entering the bacterial cell and reducing intracellular drug accumulation (Chen and Lo, 2003). 
This is achieved by decreased production of outer membrane proteins (Omps), alterations to 
the structure or composition of the Omps or the synthesis of novel Omps. Particularly OmpF 
and OmpC are involved (Chen and Lo, 2003). This mechanism also leads to decreased 
permeability to unrelated antibiotics (i.e. β-lactams, aminoglycosides, tetracyclines and 
chloramphenicol) (Brown and Reeves, 1997). However, this mechanism is not universal on 
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fluoroquinolone resistance as Salmonella sp. lacking OmpF porins did not show a decrease in 
fluoroquinolone accumulation (Chen and Lo, 2003).  
Recently, plasmid-mediated horizontally transferable genes encoding quinolone resistance 
(Qnr genes) have been discovered (Robicsek et al., 2006a). QnrA has been shown to bind 
DNA gyrase directly as well as topoisomerase IV. Hereby, QnrA minimizes opportunities for 
the quinolones to stabilise the lethal gyrase-DNA-quinolone cleavage complex (Tran et al., 
2005). According to several epidemiological surveys, QnrA was found in all populated 
continents (except South America) and in most clinically common Enterobacteriaceae 
(Robicsek et al., 2006a). 
Although these mechanisms do not allow a population to survive in the presence of a 
quinolone, as they only confer low-level resistance, they substantially enhance the number of 
resistant mutants that can be selected from the population. To define the proportion of clinical 
Enterobacteriaceae harbouring such low-level resistance and the effect of these genes on 
clinical outcome, further investigations are to be carried out (Robicsek et al., 2006a).  
 
1.1.5.  Drug interactions and toxic effects of enrofloxacin in poultry and turkeys   
To prevent a reduction in the antibacterial activity expected from enrofloxacin, and to 
optimize its clinical efficacy, some precautions must be observed when administering the drug 
to turkeys. Despite of analogue formulations, some enrofloxacin products lack bioequivalence 
which may result in lower maximum serum concentrations (Sumano et al., 2001, 2006). 
Enrofloxacin is a photosensitive molecule. Exposure of medicated water to direct light must 
be prevented (Sumano et al., 2004). Compounds containing divalent or trivalent cations, such 
as aluminium, calcium, iron, magnesium or zinc, administered concurrently with 
enrofloxacin, may reduce absorption of the fluoroquinolone (Walker, 2000b). Therefore, the 
use of galvanized water tanks, hard water as a vehicle, or food rich in magnesium or calcium 
should be avoided (Tanner, 2000; Sumano et al., 2004).  
Only few drug interactions with enrofloxacin are reported and most are of no veterinary 
significance. In chickens, enrofloxacin has been shown to inhibit liver microsomal mixed-
function oxidases in broiler chickens, including aniline hydroxylase and aminopyrine N-
demethylase (Shlosberg et al., 1995) resulting in reduced elimination of drugs that depend on 
liver metabolism for excretion. Adverse interactions with ionophore antibiotics may therefore 
be anticipated. Cytochrome P450 enzyme activity was not significantly affected in chickens 
(Shlosberg et al., 1995). In turkeys, reports concerning enrofloxacin depressing hepatic 
enzyme activity can not be found, but since the pharmacokinetics of enrofloxacin in turkeys 
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can be characterized as similar to those in chickens (Dimitrova et al., 2006), the same 
measures should be taken.  
Fluoroquinolones are relatively safe antimicrobials (Anonymous, 2003). Administered at 
therapeutic doses, toxic effects are mild and generally limited to gastrointestinal disturbances 
(Walker, 2000b). However, increased uptake of water medicated with enrofloxacin (e.g. 
because the temperatures in the stable are fluctuating) can cause cartilage lesions leading to 
arthropathies (Enrofloxacin package insert, Baytril, Bayer-US, Rev 11/00. Rec 6/10/02). 
Overdoses of enrofloxacin have been reported after administration of 626 ppm enrofloxacin in 
the drinking water to 1–day old turkey poults for 21 days. In the first 10 days, 11 out of 40 
turkeys died. Surviving birds showed signs of listlessness and decreased body weight gain 
(Veterinary Healthcare Communications, 2001). For enrofloxacin no evidence of 
carcinogenicity was found in any study of laboratory animal models (Veterinary health care 
communications, 2001). The effect on reproduction in turkeys has not yet been established. In 
chickens no effects were noted measuring the reproductive parameters (egg production, egg 
weight, hatchability, chick viability and reproductive histology of treated birds and their 
progeny). In this study, male and female chickens were given enrofloxacin at a dose of 150 
ppm in drinking water for 7 days, at different ages between 1-206 days (Veterinary Healthcare 
Communications, 2001). Because enrofloxacin is irritating to eyes and skin, safety 
precautions should be taken when administering the drug. 
 
1.1.6.  Pharmacokinetic parameters of enrofloxacin  
The pharmacokinetic parameters of a drug are largely governed by its chemical nature 
and related physicochemical properties (Baggot, 2000). They include the route of 
administration, the rate of absorption, the rate of distribution, the volume of distribution, the 
protein binding capacity of the drug and the route and rate of elimination (Walker, 2000b). 
Many reports can be found dealing with the pharmacokinetic data of enrofloxacin and 
species-specific differences have been observed (Haritova et al., 2009). Because the 
experiments in this dissertation are performed in turkeys, mainly the pharmacokinetic 
properties of enrofloxacin in this bird will be discussed.  
The pharmacokinetic values of enrofloxacin reported below were obtained after single 
(oral/intravenous) pulse administration (Haritova et al., 2004; Dimitrova et al., 2007) or after 
continuous oral dosing (Fraatz et al., 2006) of turkeys at a dose of 10 mg/kg body weight/day. 
No significant differences were noticed between sexes (Dimitrova et al., 2006).  
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After oral administration, enrofloxacin is well absorbed. The oral bioavailability of the drug 
proved to be 69.20% (Dimitrova et al., 2007). The mean absorption time was 2 hours and 45 
minutes and maximum serum concentrations (i.e. 1.23 µg/ml) were reached approximately 6 
hours after treatment (Dimitrova et al., 2007). From 10 minutes until the 24th hour inclusive, 
serum levels remained above 0.170 µg/ml. After intravenous injection serum levels were 
constantly higher than 0.20 µg/ml (Dimitrova et al., 2007). After continuous drinking water 
medication (10 mg/kg for 3 continuous days), mean serum concentrations at day three of 
treatment ranged between 0.32-0.45 µg/ml (Fraatz et al., 2006). Following absorption, 
enrofloxacin is well distributed in different tissues. Volume distributions of approximately 4 
l/kg were observed (Haritova et al., 2004; Dimitrova et al., 2007). At the third day of 
continuous enrofloxacin administration, mean concentrations in liver and lung ranged 
between 3.49-3.58 and 0.95-1.09 µg/ml, two to three times higher than the mean 
concentrations found in serum (Fraatz et al., 2006), indicating very good drug penetration into 
the deep respiratory tract. Enrofloxacin concentrations are higher in infected tissues compared 
to healthy tissues, probably because fluoroquinolones rapidly accumulate in leukocytes. In 
addition, because they are distributed into the cytosol, intracellular pathogens can be reached 
(Papich and Riviere, 2001). The elimination half-life (t1/2) of enrofloxacin is long, making the 
drug ideal for q12-q24-hour dosing regimens. After single oral administration at 10 mg/kg 
body weight t1/2 was 6.92 +/-0.97 h. The mean residence time (MRT) was 11.91 +/- 1.87 h. 
After intravenous injection t1/2 was 6.64 h (+/- 0.90 h) and MRT 8.96 h (+/- 1.18 h) 
(Dimitrova et al., 2007). Enrofloxacin is partially metabolized in the liver, yielding the 
metabolites ciprofloxacin, dioxociprofloxacin, oxociprofloxacin, N-formyl ciprofloxacin, 
enrofloxacin amide, desethylene enrofloxacin, oxoenrofloxacin and hydroxyl oxoenrofloxacin 
(Dimitrova et al., 2007). The major metabolite is ciprofloxacin, the only metabolite with 
antimicrobial activity (Anonymous, 2003). In turkeys, a fast but low-level biotransformation 
of ciprofloxacin can be observed with serum concentrations being < 7.68% of the parent 
substance (Fraatz et al., 2006; Dimitrova et al., 2007). Also in body tissues, ciprofloxacin 
levels were low (< 5% of the total antimicrobial concentration) except in the liver where 
levels exceeded 40% (Fraatz et al., 2006). However, because of the usually lower MIC of 
ciprofloxacin for pathogens, Dimitrova et al. (2007) evaluate the combined action of 
enrofloxacin and ciprofloxacin as important. Besides the bile, enrofloxacin is mainly excreted 
in the urine (Dimitrova et al., 2007). Reported body clearance (Clb) values are 0.47 l/kg/h 
(Haritova et al., 2004) and 0.41 l/kg/h (Dimitrova et al., 2007). 
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The pharmacokinetics of enrofloxacin can be characterized as similar to those in chickens 
(Dimitrova, 2007).  Half-life and mean maximum serum concentrations are almost the same 
as in chickens (Bugyei et al., 1999; Garcia Ovando et al., 1999; Sumano et al., 2001). In 
contrast with chickens, the process of absorption after oral administration seems delayed and 
also the biological half-life and mean residence time are longer (Anadon et al., 1995; Abd- El-
Aziz et al., 1997; Bugyei et al., 1999; Knoll et al., 1999; Sumano et al., 2001). A hypothetical 
cause for these differences could be the experimental conditions, the species and breed 
peculiarities, and the difference in the body weight of the treated birds (Dimitrova et al., 
2007). 
 
1.1.7.   Pharmacodynamic parameters of enrofloxacin  
Antimicrobial pharmacodynamics describe the impact of an antimicrobial agent on a 
target pathogen and are based on the drug’s pharmacokinetics and microbiological activity 
toward that pathogen, together with the pathogen’s susceptibility (Rybak, 2006). 
Pharmacodynamic properties include drug concentration over time in the tissue and other 
body fluids,  drug concentration over time at the site of infection, and antimicrobial effect at 
the site of infection. Pharmacodynamic antimicrobial measures and effects at the site of 
infection include minimal inhibitory concentration (MIC), minimal bactericidal concentration 
(MBC), concentration-dependent killing effect, post-antibiotic effect (PAE), sub-MIC post-
antibiotic effect (SM-PAE), and post-antibiotic leukocyte enhancement effect (PALE) 
(Walker, 2000b). 
The minimal inhibitory concentration or MIC of an antimicrobial is defined as the lowest 
concentration of an antimicrobial that will inhibit the visible growth of a standardised 
inoculum of approximately 105 cfu/ml micro-organisms after overnight incubation (Andrews, 
2001). The MICs that inhibit 50% and 90% of a collection of field isolates are defined as 
MIC50 and MIC90, respectively. MICs have a pivotal role as prime pharmacodynamic 
predictor factor in designing dosing regimens (Frimodt-Moller, 2002). Although low MICs 
generally indicate greater in vitro potency, these values must be interpreted in relation to 
achievable serum and tissue concentrations of the drug (Walker, 2000a). Bacteria with MICs 
< 0.25 µg/ml are regarded susceptible to enrofloxacin, bacteria with MICs between 0.5-1 
µg/ml intermediate susceptible and bacteria with MICs > 2 µg/ml considered resistant to 
enrofloxacin (CSLI guidelines, M31-A3, 2008).  
Enrofloxacin exhibits bactericidal action. The minimal bactericidal concentration (MBC) is 
the lowest concentration of an antimicrobial drug that causes at least a 3 log10 reduction in the 
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number of surviving bacterial cells compared to the initial pre-incubation inoculum after 18-
24 hours of incubation (Prescott and Walker, 2000). For enrofloxacin, the bactericidal 
concentrations are equal to or barely twice as high as the MIC (Pirro et al., 1997).  
Enrofloxacin exerts a concentration-dependent killing. Whenever the concentration of the 
fluoroquinolone increases above the MIC of the pathogen, the number of viable organisms 
decreases dramatically, because of increased killing (Prescott and Walker, 2000). As the ratio 
of enrofloxacin concentration to MIC increases from 1:1 to the bactericidal concentration, a 
bacterial reduction of more than 3 log10 cfu/ml (i.e. 99.9% of the bacteria) is achieved within 
6 hours of exposure (Maxwell and Critchlow, 1998). Unfortunately, fluoroquinolones also 
exhibit a biphasic dose response curve. They are less active at concentrations below or much 
higher than the MIC (Brown, 1996). As mentioned before, the decrease in antimicrobial 
activity at high drug concentrations is thought to be caused by inhibition of protein or RNA 
synthesis, resulting in bacteriostasis (Smith and Zeiler, 1998).  
The post-antibiotic effect (PAE) of enrofloxacin refers to the persistent suppression of 
bacterial growth following initial exposure and subsequent removal of the drug. The length of 
the PAE depends on the microorganism, the duration of exposure and the concentration of the 
drug to which the bacteria are exposed (Prescott and Walker, 2000). At concentrations of 10 
times the MIC prior to drug withdrawal, the PAE of enrofloxacin for Pasteurella  multocida 
was 3.2 h (Fera et al., 2002). At concentrations of 8 times the MIC prior to drug withdrawal, 
the PAE of enrofloxacin for E. coli was 1.9 h (Wang et al., 2003).  
When there is a slow removal of the drug from the site of infection, a sub-inhibitory drug 
concentration may continue to inhibit DNA and protein synthesis (Prescott and Walker, 
2000). This is called the sub-MIC post antibiotic effect and can be measured by exposing the 
bacterium to a concentration corresponding to half the MIC, following primary drug exposure 
and drug removal (Prescott and Walker, 2000). This effect is important for pulsed-dose 
medication, as enrofloxacin concentrations decline for some time below level of bacteriostatic 
or bactericidal activity between successive medication days (Baggot, 2000). Because of its 
variable duration, generally 1-6 hours, PAE is not taken into account when calculating dosage 
regimens (Baggot, 2000). 
Finally, for enrofloxacin a post-antibiotic leukocyte enhancement effect (PALE) is reported. 
PALE describes a bacterium’s increased susceptibility to phagocytosis and intracellular 
killing following drug exposure (Prescott and Walker, 2000) and can be ascribed to the 
immunomodulatory effects of enrofloxacin. 
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1.1.8.   PK/PD parameters defining dosing strategies  
To predict the efficacy of an antimicrobial compound, specific PK/PD parameters are 
commonly used. For fluoroquinolones, which are concentration-dependent, these parameters 
are the ratio of maximum serum concentration to the minimum inhibitory concentration 
Cmax/MIC and the ratio of the area under the curve of the plasma concentration over time 
(AUC) to the MIC (AUC/MIC) (Frimodt-Moller, 2002; Ryback, 2006). The higher these 
ratios are, the better the cure rate (reduction of clinical symptoms, clearance of the pathogen 
from the site of infection) and the lower the chance that less drug-sensitive or drug-resistant 
microorganisms will emerge (Frimodt-Moller, 2002). Athough a strong correlation exists 
between both ratios (correlation coefficient of 0.92) (Forrest et al., 1993), the AUC/MIC ratio 
correlates best with clinical outcome and the Cmax/MIC ratio is the more appropriate measure 
for assessing the potential for emergence of less susceptible or resistant microbial 
subpopulations (Ambrose, 2003).    
Many studies, primarily performed in Gram-negative bacteria, have concluded that for clinical 
and microbiological success and to limit the development of bacterial resistance AUC/MIC 
ratios of >100-125 or Cmax/MIC ratios of >10 are required (Blaser et al., 1987; Madaras-Kelly 
et al., 1996, Frimodt-Moller, 2002). In turkeys, the pharmacodynamic predictors of 
enrofloxacin, orally given at 10 mg/kg body weight, for clinically significant microorganisms 
whose MIC varied from 0.008 µg/ml to 0.125 µg/ml were determined by Dimitrova et al. 
(2007). Cmax/MIC ranged from 161.23 +/- 5.9 h to 12.90 +/-0.5 h and AUC0→24/MIC rated 
from 2153.44 +/- 66.6 h to 137.82 +/- 4.27 h. Similar results were found by Fraatz et al. 
(2006) whereas mean enrofloxacin concentrations in the lung after continuous drinking 
medication at 10 mg/kg body weight exceeded MIC90 values for E. coli (0.06 µg/ml) by 
approx four log2, for P. multocida (0.16 µg/ml) by six steps, for O. rhinotracheale (0.25 
µg/ml) by two steps, for M. gallisepticum (0.1 µg/ml) by three steps and M. synoviae (0.5 
µg/ml) by one step. These high values should provide a maximal clinical and microbiological 
effect, and a good condition to minimize the risk of appearance of antimicrobial resistance in 
this bird species. 
Certain limitations are involved with the application of the pharmacodynamic predictors in 
designing dosing strategies. First, there is a considerable variation in pharmacodynamic 
measures and outcome parameters appear to be quinolone and pathogen specific. Secondly, 
unsolved questions regarding optimal pharmacodynamic outcome predictors for Gram-
positive bacteria, anaerobes and atypical respiratory pathogens remain (Wright et al., 2000). 
  General introduction  
___________________________________________________________________________ 
 22 
In addition, Zhao and Drlica (2008) argue that dosing strategies based on the previous 
predictors fail to consider resistant mutant subpopulations as only bulk population 
susceptibility, measured by MIC, is being addressed. Therefore, another strategic approach is 
to use the mutant selection window hypothesis (Drlica, 2003). The mutant selection window 
is an antimicrobial concentration range extending from the minimal concentration required to 
block the growth of wild-type bacteria (MIC99) up to that required to inhibit the growth of the 
least susceptible, single-step mutant. The upper boundary is called the mutant prevention 
concentration (MPC). Consideration of the mutant selection window leads to the suggestion 
that antimicrobial concentrations between MIC and MPC enrich mutant subpopulations 
selectively. If antimicrobial concentrations are kept above mutant prevention concentration 
throughout therapy, mutant subpopulation (single-step mutants) amplification will be 
inhibited (Zhao and Drlica, 2008). For fluoroquinolones the MPC corresponds to AUC24/MIC 
> 200 (Drlica, 2003). However, when an antimicrobial agent like enrofloxacin for example 
has two intracellular targets (DNA gyrase and topoisomerase IV), a bacterial cell would have 
to acquire concurrent mutations for growth. As mutations occur at a rate of 10-14 and bacterial 
populations in infected individuals only reach 1010 cells, resistant mutants would be rarely 
recovered as the mutant prevention window would be closed (MIC = MPC) (Ng et al.,1996,  
Pan et al., 1996). Whether exceeding the MPC, which is an in vitro concept, is sufficient to 
restrict the development of resistance in vivo requires clinical testing.  
Another dosing strategy aiming at slowing down the emergence of mutational resistance is 
dose escalation modelling. It involves mathematical modelling of data obtained with 
escalating doses to identify the susceptible population-based drug exposure (AUC24/MIC) that 
blocks amplification of resistant mutant subpopulations and kills most susceptible cells.  As in 
the first strategy, problems arise from using bulk population susceptibility rather than mutant 
subpopulations susceptibility (Jumbe et al., 2003). Instead, using the MPC-based threshold 
AUC24/MPC as a target parameter for blocking resistant subpopulation proliferation would 
improve the model (Zhao and Drlica, 2008). This index for susceptible cells should apply to 
resistant subpopulations if MPC is substituted for MIC, as MPC correlates with the MIC of 
the least-susceptible single (next)-step mutant. However, more in vivo studies must be carried 
out to confirm these expectations. 
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1.2. MULTICAUSAL RESPIRATORY DISEASE IN TURKEYS 
 
Respiratory disease in turkeys is complex and involves multiple etiologies. Unfavourable 
environmental and husbandry factors such as high atmospheric ammonia levels, high dust 
levels and changes in temperature predispose for infectious respiratory agents (Kleven, 2008). 
In addition, immunosuppressive agents like hemorrhagic enteritis virus or digestive disorders 
may weaken the immune system rendering the turkeys more susceptible to respiratory 
infections (Kleven, 2008). These respiratory infections can be implicated by several 
pathogenic agents (Kleven, 2008). Avian metapneumovirus, Newcastle disease, 
Paramyxovirus 1, 2 and 3 and avian influenza are relevant associated viral infections. Also 
severe or prolonged vaccination reactions following the use of live ND or infectious 
bronchitis vaccines may result in the development of respiratory disease. Bacterial species 
commonly involved are Mycoplasma sp., E. coli, O. rhinotracheale, P. multocida, Riemerella 
anatipestifer, Bordetella avium and Chlamydophila psittaci. Finally moulds like Aspergillus 
fumigatus can also be implicated in turkey respiratory disease. However, certain infections are 
more encountered in the commercial turkey production than others. The viral agent currently 
most relevant for commercial turkey production and acting as a primarily triggering agent is 
avian metapneumovirus. E. coli and O. rhinotracheale are the two most frequently 
encountered micro-organisms causing secondary bacterial infections and severely aggravate 
the turkey respiratory disease and worsen its economic impact. In the next paragraphs these 
two important bacterial species are more thoroughly reviewed. 
 
1.2.1. Ornithobacterium rhinotracheale infections in turkeys 
 
1.2.1.1. A short history and general characteristics of O. rhinotracheale infections 
In 1991 a new respiratory disease characterized by a foamy white, yoghurt-like 
exudate in the air sacs in South African broiler chickens was reported (van Beek et al., 1994). 
Bacterial examination revealed a “Pasteurella-like” bacterium, that could not be classified as 
any of the known bacterial species. Thereupon, organisms with the same feature were isolated 
out of poultry, including turkeys, in the Netherlands and Germany (Hafez et al., 1993; Hinz et 
al., 1994; Van Beek et al., 1994). The new organism was designated several names. It was 
referred to as Pasteurella-like bacterium (Hafez et al., 1993) and Kingella-like bacterium 
(Van Beek et al., 1994). Charlton et al. (1993), the first ones to characterize the bacterium, 
called it a pleomorphic Gram-negative rod and Bisgaard (van Beek et al., 1994) stated that it 
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could be classified within a group of bacteria designated TAXON 28. In 1994 Vandamme et 
al. (1994) proposed its custom name -Ornithobacterium rhinotracheale- after identifying its 
phylogenetic position and various genotypic, chemotaxonomic, and classical phenotypic 
characteristics. O. rhinotracheale is a member of the rRNA superfamily V within the 
Cythophaga-Flavobacterium-Bacteroides phylum and closely related to Riemerella 
anatipestifer and Coenonia anatine. Afterwards, investigations of culture collections (Hinz 
and Hafez, 1997) revealed that O. rhinotracheale was already isolated from turkeys and rooks 
suffering from respiratory disease in Germany, England and California in the early eighties, 
years before the first observation in South Africa.  
Since its recognition in 1994, numerous isolations of O. rhinotracheale have been reported 
from many countries worldwide and out of a whole range of avian species: partridge, 
pheasant, pigeon, rook, quail, duck, chuckar partridge, ostrich, goose, guinea fowl, chicken 
and turkey (Charlton et al., 1993; Vandamme et al., 1994; Devriese et al., 1995; Buys, 1996; 
Abdul-Aziz et al., 1999; Joubert et al., 1999; Sakai et al., 2000). Thus, it can be assumed that 
the organism is spread all over the world. 
After incubation, oxidase-positive, catalase-negative, nonhemolytic, circular, grey to grey-
white, 1-2 mm convex colonies with an entire edge pin point and a butyric acid odor will 
appear (Chin et al., 2008). After Gram staining, a characteristic pleomorphic, rod-shaped, 
nonsporulating, Gram-negative bacterium measuring 0.2-0.9 µm in width and 0.6-5 µm in 
length is noticed (Chin et al., 2008). The most characteristic biochemical properties of O. 
rhinotracheale are: positive for oxidase, urease, β-galactosidase, arginine dehydrolase, 
alkaline phosphatase, esterase lipase, leucine arylamidase, cystine arylamidase, acid 
phosphatase, phosphohydrolase, α-glucosidase, N-acetyl-β-glucosaminidase, and acid 
production from glucose, fructose, lactose and galactose. The bacterium is negative for nitrate 
reduction, catalase, growth on McConkey agar, motility, lysine decarboxylase, indole 
production, gelatinase, esterase, lipase, chymotrypsin, β-glucuronidase, β-glucosidase, α-
mannosidase, α-fucosidase, and acid production from maltose, sucrose, fructose and ribose 
(van Empel and Hafez, 1999). 
Currently, 18 serotypes (A through R) of O. rhinotracheale have been determined. In turkeys, 
61% of the isolates belong to serotype A. Since serotype C could only be isolated from 
turkeys in South Africa and the United States, there appears to be a correlation between the 
geographic origin of the isolates and their serotype. There is no indication of host specificity 
of the serotypes (Chin et al., 2008).  
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1.2.1.2. Pathogenesis and epidemiology of O. rhinotracheale infections 
Respiratory disease has been and continues to be a significant problem for the turkey 
industry. Like in all poultry species, infections of the respiratory tract in turkeys can rarely be 
attributed to a single agent. Under commercial conditions complicated infections involving 
multiple etiologies with viruses, mycoplasmas, other bacteria, immunosuppressive agents and 
unfavourable environmental conditions are the rule rather than the exception. Besides, the use 
of live viral vaccines against Newcastle Disease or Infectious Bronchitis play a major role in 
the development of respiratory disease (Kleven, 2008). 
Taking in consideration the many reports of field cases of O. rhinotracheale infections, it is 
clear that the organism, twenty years after its discovery as the cause of a new respiratory 
disease in poultry (van Beek et al., 1994), plays a significant role in the respiratory disease 
complex. As mentioned above case reports of uncomplicated O. rhinotracheale infections in 
turkeys are scarce and usually concomitant infections with other respiratory pathogens such as 
Newcastle disease virus, avian metapneumovirus, Mycoplasma synoviae, Mycoplasma 
gallisepticum, Escherichia coli, Bordetella avium and Chlamydophila psittaci are seen in the 
field. Several researchers (DeRosa et al., 1997; Chin and Droual, 1997; van Empel and Hafez, 
1999, Zorman-Rojs, 2000, Van Loock et al., 2005; Marien, 2007) have succeeded in 
demonstrating the synergistic effect between O. rhinotracheale and these other respiratory 
pathogens frequently encountered in the field showing aggravating clinical symptoms when 
turkeys inoculated with O. rhinotracheale were challenged with concomitant infections.   
The precise role of O. rhinotracheale as either a primary or secondary pathogen is not clear 
yet. Most experimental studies have concluded that, when O. rhinotracheale is experimentally 
inoculated as single agent, the organism causes minimal pathological lesions (Back et al., 
1997; De Rosa et al., 1997; Droual and Chin, 1997; Jirjiss et al., 2004; Marien et al., 2005). 
Upon aerosol, oculonasal or intra-tracheal inoculation with O. rhinotracheale of specified 
pathogen free (SPF) birds, pneumonia or airsacculitis were never induced with O. 
rhinotracheale alone. Only after intravenous challenge meningitis, osteitis and a mortality rate 
of 20% could be induced in SPF chickens (Goovaerts et al., 1999). Airsacculitis, however, a 
lesion often observed in the field, was not reported in the experiment. In contrast with the 
situation in SPF birds, some research groups did observe pathological lesions similar to those 
seen in field cases after experimental infection of commercial birds with O. rhinotracheale. 
Ryll et al. (1996) and Sprenger et al. (1998), for example, observed airsacculitis, pneumonia 
and increased mortality after aerosol, intra-tracheal, intravenous and/or intra-thoracic O. 
rhinotracheale inoculation. Also Van Empel et al. (1996) could evoke airsacculitis and 
  General introduction  
___________________________________________________________________________ 
 26 
growth retardation after aerosol and intra-air sacs challenge. However, using commercial 
birds in experimental studies implies that their microbiological and immunological status are 
uncertain, which might have contributed to the development of lesions. Also the route of 
infection used such as intrasaccular inoculation may bypass the bird’s innate defence 
mechanisms situated at the upper respiratory tract.  
Although the question whether O. rhinotracheale is or is not a primary respiratory pathogen is 
still under debate, several studies (mostly conducted in chickens) have reported differences in 
pathogenicity between isolates of O. rhinotracheale. After inoculation into the air sacs of 
broilers, three South African isolates showed significant differences in the production of 
airsacculitis and arthritis (Travers et al., 1996). In another study in chickens, an American O. 
rhinotracheale isolate proved to be less pathogenic compared to Dutch and South African 
isolates (Van Veen et al., 2000). In addition, Hafez and Popp (2003) classified several O. 
rhinotracheale isolates as pathogenic, moderately pathogenic or highly pathogenic on the 
basis of embryo lethality tests in chickens and turkeys. The existence of pathogenicity 
difference between O. rhinotracheale isolates could be a plausible explanation why some O. 
rhinotracheale strains appear to produce respiratory disease on their own and other isolates do 
not.  
Knowledge of the mechanisms of virulence of O. rhinotracheale is still very limited. 
Currently no special structures or properties such as pili, fimbriae or specific toxic activities 
have been reported (Chin et al., 2008). A study investigating the role of outer membrane 
proteins (Omp) in the interaction of O. rhinotracheale with tracheal epithelium showed that 
antibodies against a 53 kDa Omp resulted in a significant inhibition of bacterial adherence to 
tracheal epithelium of up to 78% (Nofouzi et al., 2007). Another study, investigating the iron 
acquisition mechanism of O. rhinotracheale, observed that several field strains of O. 
rhinotracheale were resistant to the iron chelator 2,2’-dipyridyl, suggesting that this attribute 
may be related to disease-producing potential of these strains (Tabatabai et al., 2008). It has 
been reported that one strain of O. rhinotracheale, belonging to the rare serotype K, carries a 
cryptic plasmid pOR1 (Back et al., 1997; Jansen et al., 2004). The plasmid was probably 
introduced on a single recent occasion as it has not spread in the population. However, based 
on this cryptic plasmid pOR1, a construct plasmid shuttle vector pOREC1 has recently been 
constructed (Jansen et al., 2004). This transformation of O. rhinotracheale could pave the 
way to genetic manipulation of this bacterium and could aid in a better understanding of the 
virulence producing potential of O. rhinotracheale strains. 
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Transmission of O. rhinotracheale occurs horizontally by direct contact or indirectly through 
aerosols or drinking water. Since the bacterium has been isolated from the sexual apparatus 
(ovaries and oviduct), hatching eggs, infertile eggs, dead embryos and dead-in-shell turkeys, 
O. rhinotracheale also seems to spread vertically (Chin et al., 2008), which was confirmed by 
experimental studies performed by van Veen et al. (2004). Outbreaks of O. rhinotracheale 
infections occur more often during the winter months (Chin et al., 2008). This is explained by 
the longer survival period of the organism at lower temperatures (6 days at 22°C, 40 days at 
4°C) (Lopes et al., 2002c). 
 
1.2.1.3. Clinical symptoms observed during O. rhinotracheale outbreaks in turkeys 
O. rhinotracheale can cause an acute, highly contagious disease in turkeys. The 
severity of clinical signs, the duration of the disease and the mortality rate of O. 
rhinotracheale outbreaks are, however, extremely variable. They can be influenced by 
concurrent diseases, secondary infections, and possible also due to a pathogenicity difference 
between O. rhinotracheale strains. Viruses affecting the respiratory tract like avian 
metapneumovirus, Newcastle disease virus or Infectious bronchitis virus are regarded as 
important triggering agents. In addition, environmental factors such as poor management, 
inadequate ventilation, high stocking density, poor litter conditions, poor hygiene, high 
ammonia levels, can seriously aggravate clinical disease (Van Empel and Hafez, 1999; Chin 
et al. 2008). 
Generally, the clinical disease observed in turkeys is more severe than in broilers (Chin et al., 
2008). Initial symptoms are coughing, sneezing and nasal discharge, followed, in some cases, 
by severe respiratory disease, prostration and sinusitis. These symptoms are accompanied 
with a reduction of feed consumption and water intake (Chin et al, 2008). In turkey breeder 
flocks, a decrease in egg production and an increase in the number of unsuitable hatching 
eggs can be observed (De Rosa et al, 1996; Van Empel and Hafez, 1999). In addition, O. 
rhinotracheale has been reported to cause nervous signs, paralysis (motor disturbances, 
recumbency, abnormally carriage of the head), arthritis, meningitis, osteitis and osteomyelitis 
(Van Empel and Hafez, 1999; Szalay et al., 2002). Turkeys are mostly affected between 2 and 
8 weeks of age and also when older than 14 weeks (Chin et al., 2008). Mortality rates of up to 
50% are reported, but normally mortality ranges between 1-15% (Chin et al., 2008). Clinical 
disease is more severe in heavier birds. The higher mortality in toms than in hens has 
therefore been associated with their higher weight (DeRosa et al., 1996).  
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1.2.1.4. Macroscopic and microscopic lesions associated with O. rhinotracheale infections 
in turkeys  
Gross lesions associated with O. rhinotracheale infections in turkeys are rhinitis, 
edema and unilateral or bilateral consolidation of the lungs and fibrinous exudate in the air 
sacs and on the pleura. In addition, mild tracheitis, peritonitis and pericarditis occasionally 
occur (van Empel and Hafez, 1999; Chin et al. 2008). Besides, yoghurt-like exudate in the air 
sacs, a feature usually seen in chickens, is sometimes observed (personal observation). In 
some cases, swelling of the liver and spleen, as well as degeneration of heart muscles, have 
been noticed (van Empel and Hafez, 1999). In older birds infection of the joints and vertebrae 
can be seen (Chin et al., 2008) and Szalay et al. (2002) report fibrinopurulent inflammation of 
the cranial bones and meningitis.  
The following microscopic lesions have been associated with O. rhinotracheale infections in 
turkeys in field cases (De Rosa et al., 1996; Chin et al., 2008): congested lungs, large 
collections of fibrin admixed with macrophages and heterophils lying free within the lumen of 
air capillaries and parabronchi through the parenchyma, pronounced and diffuse interstitial 
infiltrates of macrophages with smaller numbers of heterophils, coalescing foci of necrosis 
usually filled with dense aggregates of necrotic heterophilic infiltrate or exudate and often 
centered within the lumen of parabronchi with extension of the necrosis into the adjacent 
parenchyma. Within these necrotic foci, small clusters of bacteria can be scattered. Also 
severely thickened and edematous pleura and air sacs with interstitial fibrin deposits, diffuse 
heterophilic infiltrate, scattered small foci of necrotic heterophilic infiltrate, and fibrosis have 
been seen (De Rosa et al., 1996; Chin et al., 2008). Experimental infections with O. 
rhinotracheale in turkeys (Marien et al., 2005) also describe an inflammatory reaction in the 
mucosa, loss of cilia and degeneration of mucous glands of the turbinates and trachea. These 
experiments, however, showed that O. rhinotracheale alone was only able to cause minor 
histological abnormalities. Viral triggering (avian metapneumovirus) resulted in histological 
lesions more comparable to those described in the field cases of De Rosa et al. (1996).  
 
1.2.1.5. Diagnosis of O. rhinotracheale infections in turkeys  
Lesions associated with O. rhinotracheale infections in turkeys are similar to those 
caused by numerous other bacteria affecting the respiratory tract, such as Escherichia coli, 
Pasteurella multocida, Riemerella anatipestifer and Chlamydophila psittaci. Therefore, 
clinical signs and necropsy findings are of little value for diagnosis (Van Empel and Hafez, 
1999; Chin et al., 2008) and bacterial culture is best carried out. 
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Isolation of O. rhinotracheale occurs preferably from the trachea, tracheal swabs, lungs and 
air sacs. Also the nasal cavity and the infraorbital sinuses can be used for isolation. However, 
because of overgrowth of other bacteria, O. rhinotracheale can be easily masked (Van Empel 
and Hafez, 1999; Chin et al., 2008). Under field conditions, O. rhinotracheale has also been 
isolated out of the pericardium and peritoneum (De Rosa et al., 1996) but until now never 
from the heart, spleen or liver (van Empel and Hafez, 1999; Chin et al., 2008). After 
experimental O. rhinotracheale infection, however,  positive cultures from these organs have 
been obtained as well as from the joints, brains, ovary and oviduct and kidney (van Beek et 
al., 1994; Back et al., 1998b; Sprenger et al., 1998; Marien et al., 2005).  
The conditions for optimal growth are incubation on Columbia agar with 5% sheep blood 
(sheep blood agar) for at least 48 hours in a CO2-enriched atmosphere (5-10% CO2). To 
suppress overgrowth by fast-growing bacteria, gentamicin and polymyxin can be added to the 
sheep blood agar, both at 5 µg/ml. However, sheep blood agar without these additives should 
always be included, since only 90% of O. rhinotracheale strains are resistant to these 
antimicrobials (van Empel and Hafez, 1999). O. rhinotracheale grows readily on tryptose soy 
agar, on chocolate agar as well as in peptone water and pasteurella broth aerobically and 
anaerobically (Hafez, 1998; Chin et al., 2008). 
Based on its biochemical properties, identification of O. rhinotracheale can be done using the 
API-20NE system (BioMèrieux, France) after which 99.5% of the O. rhinotracheale strains 
result in a code 0-2-2-0-0-0-4 or 0-0-2-0-0-0-4 (Hafez, 1998). The API-ZYM systems 
(BioMèrieux, France) result consistently in negative reactions for lipase, β-glucuronidase, β-
glucosidase, α-mannosidase, α-fucosidase and high identification scores (4-7-2-2-6-4, 4-7-6-
2-6-4, 6-7-6-2-6-4, 6-7-2-2-6-4) were also seen using the RapID NF Plus system (Innovative 
Diagnostics, USA) (Post et al., 1999).  In addition, identification of the fatty acid profile 
(Charlton et al., 1993), a rapid slide agglutination test (Back et al., 1998) and an agar gel 
precipitation (van Empel et al., 1997) can be used to identify O. rhinotracheale isolates. 
Immunohistochemical staining, immunofluorescence staining and PCR assays are also useful 
for identification purposes (van Empel and Hafez, 1999; Chin et al., 2008). 16sRNA gene 
sequencing and also repetitive-PCR fingerprinting techniques using the primers ERIC 
(enterobacterial repetitive intergenic consensus) 1R and M13 have been used as well (van 
Empel and Hafez, 1999). Both ERIC 1R and M13 revealed different rep-PCR patterns, but the 
M13 fingerprinting technique was found to be more discriminating in differentiating O. 
rhinotracheale isolates to the serotype level (Amonsin et al., 1997; Thachil et al., 2007).  
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Finally, serology is efficient as an aid in the diagnosis of O. rhinotracheale and is also useful 
for flock monitoring. Testing for antibodies has been described by serum plate agglutination 
(Back et al., 1998a), agar gel precipitation, immunoperoxidase test (van Empel et al., 1997), 
DOT-immunobinding assay (Erganis et al, 2002) and enzyme-linked immunosorbent assays 
(also commercial ELISA kits are available (Biocheck, Gouda)) (Hafez, 2002).  
 
1.2.1.6. Treatment of O. rhinotracheale infections in turkeys and preventive measures  
Several antimicrobial sensitivity studies have demonstrated that acquired resistance 
against antimicrobials commonly used in poultry such as amoxicillin, ampicillin, doxycycline, 
enrofloxacin, flumequine, gentamicin, lincomycin, trimethoprim-sulfonamide, tetracycline 
and tylosin is very high (Devriese et al., 1995; 2001; Dudouyt et al., 1995; van Veen et al., 
2001; Soriano et al., 2003). As the susceptibility of O. rhinotracheale to antimicrobials is 
highly inconsistent and seems to depend on the geographical location of the strain (Chin et al., 
2008), antimicrobial treatment of O. rhinotracheale infections in turkeys and poultry should 
always go with vigilant sensitivity testing.   
Several studies on vaccination of turkeys against O. rhinotracheale infection have been 
reported. Vaccinations based on inactivated whole-cell formulations (bacterins in oil 
adjuvant) have shown to induce protective immunity against homologous O. rhinotracheale 
infections in turkeys (van Empel and Hafez, 1999; Sprenger et al., 2000, Van Veen et al., 
2004). Vaccination of turkey breeders with an injectable bacterin reduced vertical 
transmission but vaccination of the progeny is needed to resist challenge at 6 weeks of age 
(Van Veen et al., 2004). Unfortunately, most of these bacterins in oil adjuvans do not induce 
cross-protection against other serovars (van Empel and Hafez, 1999). However, because of 
the high variety of serotypes in turkeys (only 61% of the O. rhinotracheale isolates in turkeys 
belongs to serotype A compared to 97% in chickens), protection against multiple serotypes is 
necessary. Shuijffel et al. (2005; 2006) succeeded in developing a four component subunit 
vaccine, based on recombinant cross-protecting antigens, that protects against challenge with 
a heterologous O. rhinotracheale serotype. A disadvantage of oil adjuvant vaccines is that 
they can cause local reactions and sometimes have negative effects on the performance of the 
birds (Chin et al., 2008). Also, the way of administering these inactivated vaccines 
(subcutaneous injection) is costly and impractical in commercial flocks. Vaccination with 
attenuated O. rhinotracheale strains could avoid these negative side effects. Sprenger et al. 
(2000) vaccinated turkeys intranasally with a live O. rhinotracheale vaccine resulting in the 
protection of turkeys against pathologic changes after an intratracheal challenge with a 
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virulent O. rhinotracheale. Lopes et al. (2002a, 2002b) developed a temperature sensitive 
mutant of O. rhinotracheale and used it as a live vaccine administered in the drinking water to 
turkeys minimizing pathological changes after O. rhinotracheale infection. Roepke (2001) 
administered an autogenous live vaccine orally protecting turkeys against O. rhinotracheale 
infection even when the turkeys were simultaneously vaccinated with a live paramyxovirus 1 
vaccine. This finding is remarkable, since in practice all investigated O. rhinotracheale strains 
have been pathogenic after viral priming (van Empel and Hafez, 1999) making practical use 
so far impossible. 
 
1.2.2. Avian pathogenic Escherichia coli infections in turkeys 
 
E. coli is a Gram negative, non-sporulating, rod-shaped bacterium of the family 
Enterobacteriaceae present in the normal microbiota of the avian intestinal tract. A certain 
number of these strains, however, designated as avian pathogenic E. coli (APEC), possess 
particular virulence attributes which enables them to cause disease responsible for severe 
economic losses to all poultry producers worldwide (Dho-moulin and Fairbrother, 1999; 
Vandekerchove, 2004; Barnes et al., 2008; Dziva and Stevens, 2008). 
Colibacillosis refers to any localized or systemic infection caused primarily or secondarily by 
APEC, and may include colisepticemia, air sac disease or chronic respiratory disease (CRD), 
swollen-head syndrome, osteomyelitis/synovitis or turkey osteomyelitis complex, 
coligranuloma aka Hjarre’s disease, venereal colibacillosis, coliform cellulitis, peritonitis, 
salpingitis, orchitis, panophtalmitis, omphalitis/yolk sac infection and enteritis (Barnes et al., 
2008). Since already several thorough reviews on APEC and colibacillosis in poultry exist 
(Barnes et al., 1994, 2008; Gross, 1994; Dho-Moulin and Fairbrother, 1999; Vandemaele et 
al., 2002, Awers et al., 2003; La Ragione et al., 2004; Vandekerchove, 2004; Rodriguez-Siek 
et al., 2005; Dziva and Stevens, 2008) the following paragraphs will focus on respiratory 
colibacillosis in turkeys.  
 
1.2.2.1. Respiratory colibacillosis 
Respiratory colibacillosis is the most common feature of colibacillosis in chickens and 
turkeys. Starting as a respiratory tract infection, it may evolve into bacteraemia and a 
generalized infection which manifests as a polyserositis (Barnes et al., 2008; Dho-Moulin and 
Fairbrother, 1999). When the respiratory mucosa is damaged, APEC strains easily succeed in 
entering the blood stream (Barnes et al., 2008). Excessive ammonia levels from poor 
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ventilation or faecal degradation in wet litter and fluctuations between low and high 
temperatures are non infectious agents that can primarily affect the respiratory tract. In 
addition, infectious agents such as avian metapneumovirus and Mycoplasma sp., but also live 
vaccine strains of Infectious bronchitis virus or Newcastle disease virus (Ficken et al., 1987; 
Kleven et al., 2008) can typically predispose the respiratory tract in turkeys. An increased 
susceptibility of turkeys to colisepticemia is also promoted by other bacterial respiratory 
pathogens like O. rhinotracheale and Chlamydophila psittaci (Barnes et al. 2008; Kleven et 
al., 2008; Marien, 2008).  
Lesions are prominent in the trachea, lungs, air sacs. Infected airsacs are thickened and often 
have caseous exudate in the respiratory surface. Common in turkeys are pneumonia and 
pleuropneumonia. Lesions in the pericardial sac and peritoneal cavities are often observed in 
the subacute polyserositis stage of colibacillosis (Barnes et al., 2008). Microscopically, first 
changes consist of edema and heterophil infiltration. Macrophages are seen from 12 hours 
after inoculation and become the predominant inflammation cells, with giant cells along 
margins of necrotic areas. Lesions are further characterized by fibroplast proliferation and 
accumulation of vast numbers of necrotic heterophils in caseous exudate, in which numerous 
E. coli bacteria are present (Barnes et al., 2008). 
O-serotyping is the most frequently used typing method for diagnostic purposes and therefore 
often used for APEC description. E. coli serotypes mostly identified in disease outbreaks are 
O1, O2 and O78 (Barnes et al., 2008; Dziva and Stevens, 2008). However, these serotypes 
can also be recovered from the faeces of healthy birds (Rodriguez-Siek et al., 2005), 
reinforcing the suggestion that the intestinal tract may be an important natural reservoir for 
APEC and that predisposing factors may be required to produce disease.  
 
1.2.2.2. Virulence associated factors in APEC 
  As mentioned before, the respiratory tract is a significant route of entry into the host, 
whilst the intestinal tract has been reported to be a reservoir for both pathogenic and non-
pathogenic strains. APEC have shown to express several adhesins (fimbrial or non fimbrial) 
that could enhance preferential colonization of different sites. Colonization of multiple organs 
occurs in birds that survive septicaemia (Dziva and Stevens, 2008). 
How APEC reaches the bloodstream is not yet clarified. Whether there is a direct invasion 
after damage of the respiratory epithelia or APEC gain entry following uptake by 
macrophages is unknown (Dziva and Stevens, 2008). In O2 strains, the adhesin ibeA seems to 
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play a role (Germon et al., 2005). However, ibeA is also detected in APEC O78 from healthy 
birds (Rodriguez-Siek et al., 2005). 
Although tending to be less toxic than mammalian pathogenic E. coli, APEC has been shown 
to produce several toxins: a vacuolating autotransport toxin, enterohaemolysin, cytotoxic 
necrotic factor 1, cytolethal distending toxin and cytotoxin designated VT2y (Barnes et al., 
2008; Dziva and Stevens, 2008). In addition, APEC posses genes that encode iron acquisition 
mechanisms (such as aerobactin, yersiniabactin, sit, and iro systems) to sequester iron from 
the body fluids. These genes are considered pivotal for virulence and are significantly less 
common in commensal E. coli strains (Rodriguez-Siek et al., 2005). Also believed to play an 
important role in APEC virulence are serum resistance mechanisms protecting against 
complement-mediated lysis and opsonophagocytosis. Resistance is related to structural factors 
such as a smooth LPS layer or a particular LPS type, certain outer membrane proteins and 
specific capsule types (Barnes et al., 2008; Dziva and Stevens, 2008). Finally, other 
mechanisms that have been reported are biofilm formation (Barnes et al., 2008) and virulence 
gene regulators (Dziva and Barnes, 2008). 
It is generally believed that respiratory colibacillosis is a secondary disease. However, having 
acquired all these genes that encode virulence factors suggests that certain clones of APEC 
may be especially adapted to a life as a pathogen (Rodriguez-Siek et al., 2008). 
Vandekerchove et al. (2005) observed that certain virulence associated traits were 
significantly more prevalent in APEC isolates from colibacillosis outbreaks with high 
mortality. Nevertheless, a virulence factor existing in APEC but not detected in faecal E. coli 
strains from clinically healthy poultry, has not yet been identified (Barnes et al., 2008). 
 
1.2.2.3. Diagnosis, treatment and prevention of respiratory colibacillosis 
The clinical signs and the presence of the typical macroscopic lesions are a first 
indication for respiratory colibacillosis. Isolation of APEC from the affected organs on Mac 
Conkey agar, eosin-methylene blue or drigalki agar confirms the diagnosis. Further 
identification is based on biochemical tests. Slide agglutination tests can be performed to 
verify the serotype of the strain. Recently, a multiplex PCR has been developed to detect a 
specific constellation of 6 virulence genes (sitA, iroN, hlyF, iss, iutA, and etsA) that appear to 
characterize virulent strains identified in >74% of APEC isolates, but occur infrequently in 
commensal strains (Barnes et al., 2008). 
Respiratory colibacillosis is mainly treated with antimicrobials, but APEC isolates are 
frequently resistant to one or more drugs (Barnes et al., 2008). Avoiding the introduction of 
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pathogens that promote APEC infection in the turkeys, vaccinating the birds against 
respiratory pathogens and maintaining optimal environmental conditions are highly important 
in reducing the risk of respiratory colibacillosis. Measures that minimize dust and ammonia 
accumulation such as proper ventilation and good litter quality are fundamental since 
ammonia affects the clearance capacity of the respiratory tract and inhalation of dust 
contaminated with APEC is the most important source for infecting turkeys (Dho-Moulin and 
Fairbrother, 1999; Barnes et al., 2008).  
Some vaccines against APEC have been developed in turkeys. Effective inactivated vaccines 
have been produced (Arp, 1992; Trampel et al., 1997), but they do not provide significant 
cross-protection against heterologous serogroups. Turkeys vaccinated with a carAB mutation 
of a virulent O2 serotype were protected against collibacillosis in a wildtype challenge model 
(Kwaga et al., 1994). In addition, antiserum prepared in rabbits against iron-regulated outer 
membrane proteins of E. coli protected turkeys against mortality and reduced significantly 
macroscopic lesions and bacterial multiplication in the respiratory tract (Bolin and Jensen, 
1987)  (Barnes et al., 2008). Although in Europe, a commercial vaccine is available for broiler 
breeders containing F11 fimbrial antigen and flagellar antigen, currently, no procedure has 
proved to be highly efficacious in commercial production and no product is used widely in the 
industry at the present time (Barnes et al., 2008).  
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AIMS 
 
Respiratory disease in turkeys are induced by various viral and/or bacterial pathogens and are 
the cause of severe economic losses due to growth retardation, increased feed conversion 
rates, high medication costs, increased mortality rates and higher condemnation rates at 
slaughter. Ornithobacterium rhinotracheale and Escherichia coli are two bacterial species 
which play a significant role in the aetiology of the respiratory disease complex.  
The current labelled dosage schedule of enrofloxacin for the treatment of bacterial respiratory 
disease caused by O. rhinotracheale or E. coli in turkeys and poultry advises a continuous 
drinking water treatment at 10 mg/kg BW for 5 successive days. Although the labelled dosage 
proves very efficacious, the regimen is regarded as cumbersome for many farmers, since the 
medicated drinking water has to be prepared freshly every day for five days. In addition, in 
vivo emergence of diminished susceptibility or even resistance to fluoroquinolones is 
commonly encountered in poultry amongst many bacterial species. 
Over the last decade, dosage strategies have been developed for the fluoroquinolone 
antimicrobials which may increase their efficacy and may reduce the selection pressure for 
resistance. Nevertheless, controlled clinical studies which address such increased efficacy or 
minimal selection of resistance against O. rhinotracheale and E. coli infection have not been 
reported.  
 
In view of the above, the aim of this research was to optimize the current enrofloxacin dosage 
regimen, by modifying  
- the duration of the treatment 
- and/or the daily administered enrofloxacin concentrations 
in order to improve clinical and antimicrobial efficacy against respiratory disease caused by 
avian metapneumovirus (APV)/O. rhinotracheale and APV/E. coli infections in turkeys and 
to reduce the selection of less susceptible or resistant isolates. 
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Summary 
Drinking water treatment with enrofloxacin is widely used to cure respiratory 
infections in turkeys. The current treatment regimen advises a five day treatment at 10 mg/kg 
body weight. Since enrofloxacin exerts a concentration-dependent activity it might be useful 
to provide the total dose of 50 mg/kg body weight in a single day treatment regimen. 
Therefore, we assessed whether single day treatment regimens with 50 mg/kg body weight 
were clinically equivalent to the advised multiple day treatment regimen with 10 mg/kg body 
weight for 5 days. For this purpose, five groups of 16 twenty-two day old turkeys were 
experimentally inoculated with avian metapneumovirus (APV) and Ornithobacterium 
rhinotracheale and subsequently treated in the drinking water with enrofloxacin, using either 
a single day treatment regimen at 50 mg/kg body weight during a 5, 10 or 20 hour period or a 
standard five day treatment regimen at 10 mg/kg body weight/ day for 20 hours. Although 
initially all dosage regimens cleared O. rhinotracheale from the trachea, four days after onset 
of treatment, O. rhinotracheale bacteria were re-excreted in the single day regimens but 
without worsening of the clinical symptoms. The five day treatment with 10 mg 
enrofloxacin/kg in turkeys provided the best results for the treatment of an O. rhinotracheale 
infection in turkeys by shortening the course and reducing the severity of clinical disease and 
by eliminating O. rhinotracheale from the respiratory tract without re-emergence. None of the 
used treatment regimens promoted the selection of bacterial clones with reduced susceptibility 
or resistance. 
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Introduction 
Respiratory disease induced by various viral and/or bacterial pathogens often affects 
turkeys during the rearing period causing severe economic losses due to growth retardation, 
increased feed conversion rates, increased mortality rates, higher condemnation rates at 
slaughter and high medication costs (van Empel & Hafez, 1999).  
Avian metapneumovirus (genus Metapneumovirus) (APV) and Ornithobacterium 
rhinotracheale (O. rhinotracheale) play a significant role in the respiratory disease complex 
(van Empel et al., 1996; Jirjis et al., 2004). Avian metapneumovirus, causing disease in most 
turkey and chicken producing countries worldwide (Cook, 2000; Van de Zande, 2001; Jirjis et 
al., 2002), also predisposes O. rhinotracheale to cause a secondary bacterial infection, thus 
aggravating the symptoms in the respiratory tract (Van Empel et al., 1996; Jirjis et al., 2004; 
Marien et al., 2005; Marien et al., 2006). This double infection frequently occurs in the field 
where O. rhinotracheale is frequently isolated after APV infections (De Rosa et al., 1996; El-
Sukhon et al., 2002) and is believed to play an important role in the respiratory problems in 
the turkey and chicken industry all over the world (Canal et al., 2003; Van Loock et al., 2005; 
Allymehr, 2006; Chansiripornchai et al., 2007). 
Pursuit of optimal environmental conditions such as good hygiene, adequate ventilation, low 
ammonia levels, optimal relative humidity levels and the prevention of simultaneous 
infections may reduce respiratory disease caused by O. rhinotracheale (van Empel and Hafez, 
1999). However, clinical O. rhinotracheale related disease requires antimicrobial treatment 
for animal welfare and to limit economic losses.  
Enrofloxacin, a fluoroquinolone antimicrobial compound, acts by inhibiting DNA gyrase and 
topoisomerase IV, two enzymes involved in the bacterial DNA replication (Martinez et al., 
2006). Its killing rate has been shown to be concentration dependent and it exerts a post-
antibiotic effect (Fera et al., 2002, Wang et al., 2003). When administered in the drinking 
water for several successive days, as currently labelled (10 mg/kg body weight (BW) for 3 to 
5 days), enrofloxacin has proven its efficacy against O. rhinotracheale infections in turkeys 
(Marien et al., 2006; Marien et al., 2007). Since fluoroquinolone antimicrobials exert a 
concentration-dependent activity (Baggot, 2000; Prescott & Walker, 2000), in this study the 
hypothesis was tested whether a single daily treatment with the same total dose of 50 mg/kg 
BW would be as efficacious against O. rhinotracheale induced respiratory disease as a five 
daily treatment of enrofloxacin at 10 mg/kg BW. In addition, single day dosing would also 
improve user convenience by reducing the workload (preparing medicated water every day 
during treatment) for the farmer. The effect of single day drinking water treatments on the 
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course of a mixed APV/O. rhinotracheale infection has never been examined. Therefore, 
single-day-dosing treatments of the same total enrofloxacin dose, administered over a period 
of 5, 10 or 20 hours per day were compared to a continuous enrofloxacin dosage to turkeys 
experimentally infected with APV and O. rhinotracheale. 
 
 
Materials and Methods 
 
Turkeys 
Eighty specified pathogen-free (SPF) turkeys (AFSSA, Ploufragan, France), hatched at 
our facilities, were used in this study. The birds were housed on litter in separate isolation 
rooms with HEPA-filtered air, had free access to feed and water and received 20 hours of 
light per day. At two weeks of age, the sera of the birds were shown to be free of maternally-
derived antibodies to APV and O. rhinotracheale by means of commercially available 
ELISA-kits (Biochek, Gouda, the Netherlands). Tracheal swabs from all birds were examined 
for the presence of O. rhinotracheale and proved to be negative. 
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during a 
respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The virus stock 
had a titre of 5.5 log10 50% ciliostatic dose (CD50)/ml after the third passage in tracheal organ 
cultures.  
 
Bacteria 
The O. rhinotracheale type strain LMG 9086T, originally isolated from a turkey with a 
respiratory tract infection, was used. The strain was serotyped as type A in an agar gel 
precipitation test (Hafez & Sting, 1999), kindly performed by Professor H. M. Hafez (Institute 
of Poultry Diseases, Free University of Berlin, Germany). The minimum inhibitory 
concentration (MIC) of enrofloxacin for the strain was determined at < 0.03 µg/ml and the 
strain was stored at -70°C. The organism was cultured for 48 h at 37°C on Columbia agar 
(Oxoid LTD, Basingstoke, Hampshire, England) with 5% sheep blood in a 5% CO2 
atmosphere. The O. rhinotracheale bacteria were transferred into brain heart infusion (BHI) 
broth (Oxoid) for 24 h at 37°C with agitation. The bacterial challenge inoculum was prepared 
by washing the cultured bacteria twice in phosphate-buffered saline (PBS) followed each time 
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by five minutes of centrifugation at 3,000 rpm at 4°C. The resulting pellet was resuspended in 
PBS to obtain a final concentration of 8 log10 colony-forming units (cfu)/ml. Confirmation of 
the number of cfu/ml was done by inoculating ten-fold dilutions in PBS on sheep blood agar 
and counting the number of colonies.  
 
Experimental design 
Eighty SPF turkeys were randomly divided into five groups and subsequently infected 
with APV at twenty-one days of age. Three days later, the turkeys were inoculated with O. 
rhinotracheale. 
All the birds of the respective groups were inoculated oculonasally with a dose of 4.4 
log10CD50 of APV and a dose of 8.5 log10 cfu of O. rhinotracheale by dividing a total of 250 
µl inoculum equally over the nostrils and eyes.  
Four groups received antimicrobial treatment by medicating the drinking water. Group E10-
5D received 10 mg enrofloxacin (Baytril 10% oral solution)/kg body weight (BW) per day for 
5 days, group E50-20H obtained 50 mg enrofloxacin/kg BW over a 20 h period, group E50-
10H 50 mg enrofloxacin/kg BW over a 10 h period and group E50-5H 50 mg enrofloxacin/kg 
BW over a 5 h period. Control group C remained untreated. Enrofloxacin was administered 
24 h after O. rhinotracheale inoculation. In every group, water uptake was measured on a 
daily basis from three days before until the end of the treatment periods. Additionally, all 
animals were weighed immediately before APV inoculation and again before O. 
rhinotracheale inoculation. On the basis of these data, the antimicrobial concentrations to be 
administered in the water and the actually received dosages were calculated. Water samples 
from the medicated drinking water were collected daily and stored at 4°C, protected from 
light, to determine the actual amount of enrofloxacin using turbulent flow 
chromatography/tandem mass spectrometry (Krebber, 2003).  
All birds were examined clinically on a daily basis throughout the experiment until 
they were sacrificed. The clinical symptoms were divided into lower respiratory tract and 
upper respiratory tract symptoms. Dyspnoea was regarded as a sign of lower respiratory 
distress. The clinical signs of the upper respiratory tract (nasal exudates, swollen sinuses, 
frothy eyes) were scored as indicated in Table 1. The mean clinical score was calculated for 
each experimental group. 
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Table 1. Scoring system for quantification of clinical signs (based on Van de Zande et al., 2001) 
Score Clinical signs 
0  
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Absence of clinical signs  
 
Clear nasal exudate 
 
Turbid nasal exudate 
 
Nasal exudate with mildly swollen infra-orbital sinuses 
 
Nasal exudate with extremely swollen sinuses  
 
Nasal exudate with extremely swollen sinuses and frothy eyes 
 
Death 
 
Tracheal swabs were taken from all birds 2 days post viral infection (pvi) for titration of APV. 
Tracheal swabs were also collected on 1, 2, 4, 6, 8, 10 and 15 or 16 days post bacterial 
infection (pbi) from all groups for titration of O. rhinotracheale. The tracheal swabs were 
collected using cotton-tipped aluminium shafted swabs (Copan Diagnostics Inc., Corona, 
USA) and placed in transport medium. The latter consisted of 1 ml PBS for bacteriological 
examination which was supplemented with 10% fetal calf serum (Gibco, Invitrogen 
Corporation, Merelbeke, Belgium), penicillin (1000 U/ml) (Biopharma, Rome, Italy) and 
kanamycin (0.5 mg/ml) (Gibco) for virus titration. Processing occurred as described below. 
Five birds of each group were sacrificed at 6 days pbi. Equal numbers of the remaining birds 
of the 5 groups were sacrificed at 15 or 16 days pbi. Euthanasia was performed by intravenous 
injection with 0.3 ml/kg BW of T61 (Intervet, Belgium). The birds were necropsied and 
examined for the presence of gross lesions.  
For the five birds of each group sacrificed at 6 days pbi, samples of the turbinates, trachea and 
lungs were collected for O. rhinotracheale examination. A 10% tissue suspension in PBS was 
prepared from these samples. Air sacs, pericardium and liver were sampled with cotton swabs 
for O. rhinotracheale re-isolation. All samples were processed immediately after collection as 
described below.   
For the remaining birds sacrificed at 15 and 16 days pbi, turbinates, trachea, lungs, air sacs, 
liver and pericardium were sampled with cotton swabs for O. rhinotracheale re-isolation.  
The birds were weighed the day before the APV infection, the day before the O. 
rhinotracheale infection and subsequently on 15 or 16 days pbi.  
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This experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine, Ghent University (EC 2007/1).  
 
Virological and bacteriological titration of tracheal swabs  
The viral titre in log10CD50 per ml and the number of cfu of O. rhinotracheale per ml 
were determined, using procedures described in Marien et al. (2005). In addition, in order to 
detect O. rhinotracheale isolates with reduced susceptibility to enrofloxacin, samples were 
also inoculated on sheep blood agar supplemented with 5 µg/ml gentamicin, 5 µg/ml 
polymyxin and 0.25 µg or 2 µg enrofloxacin/ml starting from 4 days pbi.  
 
Bacteriological examination of tissue suspensions and swabs 
From samples of the turbinates, trachea, and lungs, the cfu of O. rhinotracheale was 
determined in duplicate by incubating undiluted tissue suspensions and tenfold serial dilutions 
of tissue suspensions on sheep blood agar supplemented with 5 µg/ml gentamicin and 5 µg/ml 
polymyxin. After 24-48 h of incubation at 37°C in a 5% CO2 atmosphere, viable counts were 
performed and the number of cfu/ml tissue suspension calculated.  
The swabs taken from the air sacs, pericardium and liver from the 25 birds sacrificed at 6 dpbi 
and the swabs from the turbinates, trachea, lungs, air sacs, pericardium and liver from the 
birds sacrificed at 15 and 16 dpbi were inoculated on sheep blood agar supplemented with 5 
µg/ml gentamicin and 5 µg/ml polymyxin. After 24-48 h of incubation at 37°C in a 5% CO2 
atmosphere, the agar was examined for the presence of O. rhinotracheale colonies.  
 
Statistical analyses 
Tracheal titres of O. rhinotracheale were analysed for all birds using the 
measurements between 0 and 6 days pbi and subsequently for the birds that were not 
euthanized using the measurements between 0 and 9 days pbi. The clinical scores and weight 
were analysed only for animals that were not euthanized at 6 days pbi.  
The average over time of the clinical score and tracheal swabbing was analysed using a fixed-
effects model with the treatment group as fixed effect. 
Weight gain was compared at the end of the trial using a fixed-effects model. 
O. rhinotracheale titres from the turbinates, trachea and lung of the animals, euthanized at 6 
days pbi were compared between the five treatment groups with the Kruskall-Wallis test, 
whereas the presence of O. rhinotracheale in the airsacs, liver and pericardium of the animals, 
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euthanized at 6 days pbi were compared between the five treatments with the Fisher’s exact 
test. 
All tests were performed at a global 5% significance level and the pairwise comparisons were 
tested at an adjusted significance level using Bonferroni’s multiple comparisons technique. 
(Agresti, 2002) 
 
 
Results 
 
Antimicrobial uptake  
The actual dose for the single day medication periods was 40.8 mg/kg for group E50-
5H, 47.8 mg/kg for group E50-10H and 72.5 mg/kg for group E50-20H. The mean actual 
daily dose for group E10-5D for the total medication period was 10.4 mg/kg (range 8.61-
12.56 mg/kg).  
 
Clinical signs 
No animals died due to the APV/ O. rhinotracheale infections. 
The mean clinical scores calculated for each group are presented in Figure 1. 
Signs of upper respiratory distress were seen in all groups starting from 1 day pbi with the 
exception of 2 birds (one from group E10-5D and one from group E50-20H), which showed 
already clear nasal exudates shortly after APV infection.  
Using the average of the clinical scores from 0 to 9 days pbi, there was a significant 
difference between the 5 treatments (P = 0.0176). The control group had the highest total 
score, followed by group E50-10H, group E50-5H, group E50-20H and group E10-5D. From 
the pairwise comparisons, only group E10-5D differed significantly from the control group.  
Applying the 5 day dosing regimen, the clinical signs disappeared 4 days earlier than in the 
untreated group. In groups E50-20H and E50-5H, clinical signs disappeared 2 and 3 days 
earlier than in the control group.  
Thus, compared with the untreated control group, clinical signs were significantly reduced 
only by a multiple day drinking water treatment with enrofloxacin 10 mg/kg body weight for 
5 successive days. 
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Figure 1. Mean clinical scores in turkeys, inoculated with APV followed by O. rhinotracheale three 
days later, and treated with 10 mg/kg/day enrofloxacin for 5 successive days (group E10-5D X), 50 
mg/kg enrofloxacin for 20 hours (group E50-20H ◊), 50 mg/kg enrofloxacin for 10 hours (group E50-
10H ▲), 50 mg/kg enrofloxacin for 5 hours (group E50-5H ■), or left untreated (●).  
 
Macroscopic findings 
No macroscopic lesions were found in group E10-5D. The severity of the lesions in 
the control group and the single day treatment groups were similar, although the highest 
lesion incidence was seen in the control group.  Most birds suffered from sero- to seromucous 
exudate in the upper respiratory tract.  
In groups E50-5H and E50-20H, pneumonia was present in 2 birds of each group and 1 bird 
in group E50-10H suffered from pneumonia and airsacculitis. In the control group pneumonia 
was present in 4 animals of which 2 also had airsacculitis. 
The incidence of macroscopic lesions in the different treatment groups is shown in Table 2. 
Significant differences between treatments were observed for rhinitis (P = 0.0122) and 
sinusitis (P = 0.015). Inflammation of nostrils and sinuses was absent in group E10-5D, 
observed 4 times in group E50-5H, 8 times in group E50-20H and the control group and 9 
times in group E50-10H. 
     ↑ 
       First treatment day 
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From the 11 birds that were necropsied per group at 15 and 16 days pbi, lung lesions were 
seen in 8 birds from the control group. In group E50-20H, group E50-10H  and group E50-5H 
respectively 7, 6 and 4 turkeys showed lung lesions, whereas in group E10-5D lung lesions 
were seen in only 1 bird, with a significant difference between treatments (P = 0.0219). (Table 
2).  
 
Virological titration of tracheal swabs 
2 Days post viral infection APV was recovered from tracheal swabs of every bird. 
Mean titres were 4.6 log10CD50/ml, 4.3 log10CD50/ml, 4.3 log10CD50/ml, 4.7 log10CD50/ml and 
4 log10CD50/ml for groups E10-5D, E50-20H, E50-10H, E50-5H and the control group 
respectively.  
 
Bacteriological titration of tracheal swabs 
The results of the O. rhinotracheale titrations of the tracheal swabs are shown in 
Figure 2.  
After the first treatment day, O. rhinotracheale was hardly isolated out of turkeys treated with 
enrofloxacin. Only one turkey from group E50-10H showed very low O. rhinotracheale titres. 
This in contrast to 14 animals from the untreated control group. From 4 days pbi (group E50-
5H) and 6 days pbi (group E50-10H and group E50-20H) onwards, however, O. 
rhinotracheale was isolated from birds from the single day enrofloxacin treatment groups, 
whereas in the five day enrofloxacin treatment group O. rhinotracheale did not reappear. 
Using the average count in the fixed-effects model, there was a significant difference between 
the five treatments (P < 0.0001). For the significant pairwise comparisons between 0 and 9 
days after infection see Table 3. All enrofloxacin treatment regimens reduced the O. 
rhinotracheale counts compared to the control group. The five day treatment resulted in a 
more pronounced reduction than the single day treatments of 10 or 20 hours and the single 
day treatment of 5 hours resulted in a more pronounced reduction than the single day 
treatment of 20 hours. 
Titration of the tracheal swabs on enrofloxacin supplemented agar plates (i.e. 0.25 µg/ml agar 
and 2 µg/ml agar) did not show any growth of O. rhinotracheale at any time during the 
experiment. 
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Figure 2. Mean  O. rhinotracheale titres in tracheal swabs collected from turkeys, inoculated with 
APV followed by O. rhinotracheale three days later and treated with 10 mg/kg/day enrofloxacin for 5 
successive days (group E10-5D X), 50 mg/kg enrofloxacin for 20 hours (group E50-20H ◊), 50 mg/kg 
enrofloxacin for 10 hours (group E50-10H ▲), 50 mg/kg enrofloxacin for 5 hours (group E50-5H ■), 
or left untreated (●).  
 
Bacteriological examination of tissue suspensions and swabs  
               O. rhinotracheale was not isolated from any of the organs of the birds from group 
E10-5D. For the other groups, the mean O. rhinotracheale titres in the organs of the birds 
necropsied at 6 days pbi are shown in Table 3. 
Significant differences between treatments were observed for O. rhinotracheale titres from 
the turbinates (P = 0.0023), trachea (P = 0.0177) and lungs (P = 0.0305). The control group 
showed the highest mean scores for the turbinates and lungs, followed by group E50-10H, 
group E50-5H, group E50-20H and group E10-5D. For the trachea, group E50-5H showed the 
highest mean score, followed by group E50-10H, the control group, group E50-20H and 
group E10-5D. The only pairwise significant difference was noted for the O. rhinotracheale 
titres in the turbinates between E10-5D and the control group. From the pericard, only three  
(the control group and group E50-10H) positive samples were obtained, and from the airsacs 
only one (group E50-10H). O. rhinotracheale was not recovered from any liver sample.   
 
       ↑ 
       First treatment day 
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During the necropsies at days 15 and 16 pbi, O. rhinotracheale was recovered from the lungs 
of only one turkey from group E50-10H. O. rhinotracheale was not isolated from any other 
organ in any other bird.   
 
Weight 
After correction for gender, no significant differences (P = 0.65) were observed 
between the treatment groups.  
 
 
Discussion 
The incidence and severity of the clinical signs and macroscopic lesions, as well as the 
extent of the O. rhinotracheale tracheal and organ colonization, were reduced to the highest 
degree using the five day drinking water medication with enrofloxacin at a dose of 10 mg/kg 
BW. The effect of the three single day regimens, although significant, was less pronounced 
compared to the five day treatment. Hence, the single day dosage regimens are not a useful 
valuable alternative to the labelled dosing regimen. Five day treatment of O. rhinotracheale 
associated respiratory disease in turkeys seems therefore recommended. The current findings 
concur with the results obtained by Marien et al. (2006, 2007). The success of the high 
efficacy level of enrofloxacin is supported by several pharmacokinetic studies performed in 
turkeys (Heinen et al., 1997; Dimitrova et al., 2006; Fraatz et al., 2006). According to these 
studies, a dose of 10 mg/kg enrofloxacin given orally at 24-h intervals, results in the 
establishment of a steady state concentration in the serum and respiratory tract that is 
bactericidal for O. rhinotracheale organisms with a MIC of 0.03 µg/ml. Each of the 
enrofloxacin dosage regimens applied, was able to clear the trachea from O. rhinotracheale 
after infection, but four days after the start of the treatment, the bacteria were re-isolated in 
every single-day-treated animal group. This re-excretion did not worsen the clinical signs. A 
plausible explanation would be that in the three single-day-dosing regimens not all birds 
ingested an sufficient amount of the medicated drinking water during the limited time that 
enrofloxacin was available due to competitive behaviour at the drinkers. This would thus 
result in lower enrofloxacin levels in the plasma and the respiratory tissues of subordinate 
birds. Possible sources for the re-emergence of O. rhinotracheale in the trachea could be 
either environmental recontamination or endogenous tracheal re-colonization. It was 
hypothesized that higher plasma and respiratory tissue concentrations, subsequent to these 
higher dosages, would exert a better concentration-dependent killing. However reduction of 
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tracheal O. rhinotracheale multiplication was similar to the reduction with the 5 day treatment 
and re-excretion was only seen in the single day treatments. This indicates that the duration of 
treatment at the appropriate dosage is as important for clinical efficacy as the size of the dose 
as such. 
Acquired quinolone resistance is commonly encountered and is the consequence of stepwise 
mutations in the gyr and par genes (Barnard & Maxwell, 2001; Hooper, 2001). This means 
that after single step mutations the bacteria will become less-susceptible or even resistant after 
developing supplementary mutations. In this study, however, bacterial clones with reduced 
susceptibility or resistance were not detected in any of the enrofloxacin treated groups. This 
supports pharmacokinetic findings that, when enrofloxacin is used according to labelled 
directions for animal use, it minimizes the risk of selection for bacterial resistance. 
Antimicrobial treatment is needed for reasons of animal welfare and for control of infectious 
diseases. With antimicrobial use in commercial birds under scrutiny it should be emphasized 
that antibiotics should always be used rationally and carefully to preserve the efficacy of these 
therapeutic agents. This means that enrofloxacin should only be used where a bacterial 
infection is known or suspected to be present as determined by direct demonstration of the 
infection or from the clinical data and that sensitivity testing of enrofloxacin should be 
conducted prior to its use (Prescott, 2000).  It is also important to remember that even the best 
treatment programs can never replace good management. The positive effects of strict 
hygiene, effective biosecurity and sound flock management practices cannot be understated 
(Tanner, 2000). 
In conclusion, all enrofloxacin treatment regimens reduced O. rhinotracheale multiplication 
in the respiratory tract tissues (turbinates, trachea and lung). Although initially the single day 
dosage regimens totally cleared O. rhinotracheale from the trachea, four days after onset of 
treatment O. rhinotracheale bacteria were re-excreted but without worsening of the clinical 
signs. The five day treatment with 10 mg enrofloxacin/kg in turkeys provided the best results 
by shortening the course of clinical disease, by stopping O. rhinotracheale multiplication in 
the respiratory tract without re-multiplication, and by reducing macroscopic lesions. As no O. 
rhinotracheale grew on the enrofloxacin supplemented media, none of the used treatment 
regimens resulted in the selection of bacterial clones with reduced susceptibility to 
enrofloxacin. 
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Summary  
Escherichia coli (E. coli) infections are a common cause of respiratory disease in 
turkeys. To control these respiratory infections in turkeys, drinking water treatment with 
enrofloxacin is widely used. The current treatment schedule advises a five day treatment at 10 
mg/kg body weight. Since enrofloxacin exerts a concentration-dependent activity, it might be 
useful to provide this 50 mg/kg total dose in a single day treatment regimen. Therefore, we 
assessed whether a single day treatment schedule with 50 mg/kg body weight was clinically 
equivalent to the advised multiple day treatment schedule with 10 mg/kg body weight for five 
days. For this purpose, three groups of 17 twenty-two day old turkeys were experimentally 
inoculated with APV and three days later with E. coli. One group received 10 mg 
enrofloxacin/kg body weight in the drinking water for five successive days. The second group 
received 50 mg enrofloxacin/kg body weight for 20h in the drinking water. The third group 
was enclosed as an untreated positive control group. Both the multiple and the single day 
enrofloxacin treatment regimens reduced E. coli multiplication in the respiratory tract tissues 
(turbinates, trachea and lung) but the five day treatment with 10 mg enrofloxacin/kg in 
turkeys provided the best results by shortening the course of clinical disease, by eliminating 
E. coli from the respiratory tract without re-multiplication, and by reducing macroscopic 
lesions. The efficacy of the single day treatment did not equal that of the five day treatment, 
possibly by not eliminating E. coli from the respiratory organs, which made it possible for the 
remaining bacteria to re-emerge in those organs. None of the used treatment regimens 
promoted the selection of bacterial clones with reduced susceptibility or resistance. 
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Introduction 
Enrofloxacin, a fluoroquinolone antimicrobial compound, acts by inhibiting DNA 
gyrase and topoisomerase IV, two enzymes involved in bacterial DNA replication (Martinez 
et al., 2006). When administered in the drinking water for several successive days at 10 
mg/kg body weight, enrofloxacin has proven its efficacy against several bacterial pathogens 
causing respiratory disease in turkeys like Escherichia coli (E. coli) (Marien et al., 2007; 
Gautrais and Copeland, 1997), Ornithobacterium rhinotracheale (Marien et al., 2006; Marien 
et al., 2007) and Pasteurella multocida (Hafez et al., 1992; Gautrais and Copeland, 1997). 
Since the killing rate of enrofloxacin has been shown to be concentration dependent and 
exerts a post-antibiotic effect (Prescott and Walker, 2000), it is hypothesized that higher 
plasma and respiratory tissue concentrations, due to a higher dosage, could succeed in a better 
killing of bacteria. Therefore a single day treatment with the same total dose of 50 mg/kg 
body weight could be as efficacious as the currently labelled dose of 10 mg/kg body weight 
for 5 continuous days.  
Colibacillosis is generally agreed to be the most common infectious bacterial disease of 
poultry. It refers to any localized or systemic infection caused entirely or partly by avian 
pathogenic E. coli (APEC), including colisepticemis, coligranuloma, swollen-head syndrome, 
air sac disease, venereal colibacillosis, coliform cellulitis, peritonitis, salpingitis, orchitis, 
turkey osteomyelitis, yolk sac infection, panophtalmitis and enteritis (Barnes et al., 2008). 
These various forms of infection are responsible for severe economic losses due to growth 
retardation (Russel, 2003) and very high condemnations rates at slaughter (Yogaratnam, 1995; 
Jakob et al., 1998; Dho-Moulin and Fairbrother, 1999).  
Usually colibacillosis, affecting both chickens and turkeys, starts as a respiratory tract 
infection, evolving into a generalized infection, if unattended (Barnes et al., 2008). In turkeys, 
susceptibility to colisepticemis is increased by avian metapneumovirus infection (APV) (Van 
de Zande et al., 2001; Turpin et al., 2002; Jirjis et al., 2004), in chickens, by Infectious 
bronchitis virus and Newcastle disease virus (Ginns et al., 1998). In this study, a single-day-
dosing treatment of the same total enrofloxacin dose was compared to a five day treatment in 
turkeys infected experimentally with APV and E. coli. 
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Materials and Methods 
 
Turkeys 
Fifty-one specified pathogen-free (SPF) turkeys (AFSSA, Ploufragan, France), 
hatched in our facilities and of mixed gender, were used in this study. The birds were housed 
on litter in separate isolation rooms with HEPA-filtered air, had free access to feed and water 
and received 20 hours of light per day. At two weeks of age the birds were shown to be free 
from maternally-derived antibodies to APV, by means of a commercially available ELISA 
(Biochek, Gouda, the Netherlands). 
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during a 
respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The virus stock 
had a titer of 5.5 log10 50% ciliostatic dose (CD50)/ml after the third passage in tracheal organ 
cultures.  
 
Bacteria 
A Belgian E. coli isolate retrieved from turkeys with colibacillosis was used. It was 
identified and serotyped as O2:K1 by Dr. Flemming Scheutz (Statens Serum Institute, The 
International Escherichia and Klebsiella Centre, Copenhagen, Denmark). This strain has been 
used previously by Van de Zande et al. (2001) for establishing an E. coli infection in APV 
infected turkeys and was stored at -70°C. The minimum inhibitory concentration (MIC) of 
enrofloxacin for the strain was determined at < 0.03 µg/ml. The organism was retrieved from 
the frozen suspension and cultured overnight at 37°C on MacConkey agar. The E. coli 
bacteria were transferred into Brain Heart Infusion (BHI) and cultured for 24 h at 37°C. The 
bacterial challenge inoculum was prepared by washing the cultured bacteria twice in 
Phosphate Buffered Saline (PBS) followed each time by five minutes of centrifugation at 
3,000 rpm at 4°C. The resulting pellet was re-suspended in PBS to obtain a final 
concentration of approximately 8 log10 cfu/ml. Confirmation of the number of cfu/ml was 
done by inoculating ten-fold dilutions in PBS on sheep blood agar and counting the number of 
colonies.  
 
 
 
  Experimental studies 
___________________________________________________________________________  
 82 
Experimental Design 
Fifty-one SPF turkeys were randomly divided into three groups of 17 animals at 
twenty-one days of age. At twenty-two days of age the birds of all groups were inoculated 
with APV. Three days later the turkeys were inoculated with E. coli. 
All the birds of the respective groups were inoculated oculonasally with a dose of 4.4 
log10CD50 for APV and a dose of 7.57 log10 cfu for E. coli by dividing a total of 250 µl 
inoculum equally over the nares and eyes.  
All birds were examined clinically on a daily basis throughout the experiment until they were 
sacrificed. The clinical symptoms were divided into lower respiratory tract and upper 
respiratory tract symptoms. Dyspnea was regarded as a sign of lower respiratory distress. The 
clinical signs of the upper respiratory tract (nasal exudates, swollen sinuses, frothy eyes, 
possibly resulting in poor general condition and anorexia) were scored as described in Van de 
Zande et al. (2001). Briefly, the clinical condition of each bird was assigned a score from 0 
(absence of clinical signs) to 3 (nasal exudate with mildly swollen infraorbital sinuses) to 6 
(death).  
All the birds were weighed the day before the APV infection, the day before the E. coli 
infection and subsequently on day 15 or 16 post bacterial infection (days pbi).  
Two groups received antimicrobial treatment by medicating the drinking water. Group E10-
5D received enrofloxacin 10 mg/kg for 5 days and group E50-20H enrofloxacin 50 mg/kg for 
20h. Group C was enclosed as an untreated control group. The enrofloxacin (Baytril® 10% 
oral solution) treatments were administered 24h after E. coli inoculation. In every group, 
water uptake was noted on a daily basis from three days before treatment. Water uptake in 
each group during the different treatment periods was also noted. On the basis of these data, 
the antimicrobial concentrations to be administered in the water and the actually received 
dosages were calculated. Water samples from the medicated drinking water were collected 
daily and stored at 4°C, protected from light to determine the actual amount of enrofloxacin 
using turbulent flow chromatography/tandem mass spectrometry (Krebber, 2003).  
Before E. coli inoculation, tracheal swabs from all birds of each experimental group were 
examined for E. coli O2:K1. 
Tracheal swabs were also collected on 1, 2, 4, 6, 8, 10 and 15 or 16 days pbi from all groups 
for bacteriological titration of E. coli.  
The tracheal swabs were collected using cotton-tipped aluminium shafted swabs (Copan 
Diagnostics Inc., Corona, USA) and placed in transport medium. The latter consisted of 1 ml 
PBS for E. coli examination, supplemented with 10% fetal calf serum (Gibco, Invitrogen 
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Corporation, Merelbeke, Belgium), penicillin (1000 U/ml) (Biopharma, Rome, Italy) and 
kanamycin (0.5 mg/ml) (Gibco) for virus titration. Processing occurred as described below. 
Five birds of each group were sacrificed at 6 days pbi. The remaining birds of each group 
were sacrificed 9 and 10 days after euthanasia of the first 5 birds, i.e. 15 and 16 days pbi, in 
similar ratios of the three groups. Euthanasia was performed by intravenous injection with an 
overdose (0.3 ml/kg bodyweight) of T61 (Intervet, Belgium). The birds were necropsied and 
examined for gross lesions.  
For the five birds of each group sacrificed at 6 days pbi, samples of the turbinates, trachea and 
lungs were collected for E. coli examination. A 10% tissue suspension in PBS was made from 
these samples. Air sacs, pericardium and liver were likewise sampled with cotton swabs for E. 
coli analysis. All samples were processed immediately after collection as described below.   
For the remaining birds sacrificed at 15 and 16 days pbi, turbinates, trachea, lungs, air sacs, 
liver and pericardium were sampled with cotton swabs for E. coli analysis. A detailed 
schedule of events is illustrated in Table 1. 
This experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine, Ghent University EC 2007/01. 
 
Virological and Bacteriological Titration of Tracheal Swabs  
The viral titer in log10CD50 per ml and the number of cfu E. coli per ml were 
determined. This was done using the procedures described in Marien et al. (2005), with the 
following addition to the protocol: for the isolation of E. coli, samples were inoculated on 
MacConkey agar and incubated for 24h at 37°C. Starting from 4 days pbi samples were also 
inoculated on MacConkey agar supplemented with 0.25 µg enrofloxacin/ml agar or 2 µg 
enrofloxacin/ml agar for the detection of E. coli isolates with reduced susceptibility to 
enrofloxacin. 
The recovered E. coli isolates were serotyped by a slide-agglutination test using the antiserum 
against the E. coli O2:K1 strain (Veterinary Laboratories Agency, Surrey, United Kingdom).  
 
Bacteriological Examination of Tissue Suspensions and Swabs 
Samples of the turbinates, trachea and lungs were quantified for E. coli from the 15 
birds sacrificed at 6 days pbi. The number of cfu of E. coli per ml tissue suspension was 
determined as described in Marien et al. (2005) with the following addition to the protocol: 
for the isolation of E. coli, samples were inoculated on MacConkey agar and incubated for 
24h at 37°C.  
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The swabs taken from the air sacs, pericardium and liver from the 15 birds sacrificed at 6 days 
pbi and the swabs from the turbinates, trachea, lungs, air sacs, pericardium and liver from the 
birds sacrificed at 15 and 16 days pbi were inoculated onto MacConkey agar for E. coli 
isolation. After 24h of incubation at 37°C, the agar was examined for presence of E. coli.  
The recovered E. coli isolates were serotyped by a slide-agglutination test using the antiserum 
against the E. coli O2:K1 strain (Veterinary Laboratories Agency). 
 
Weight 
As described above, the birds were weighed the day before the APV infection, the day 
before the E. coli infection and subsequently on 15 or 16 days pbi.  
 
Statistical Analyses 
First, analyses were based on all animals, using only results from 0 to 6 days pbi. The 
mean clinical score and tracheal titer of E. coli between 0 to 6 days pbi was determined for 
each turkey and used as response variable in a fixed-effects model with the treatment group as 
fixed effect.  Second, analyses were based on turkeys that were not euthanized at day 5, using 
results between 0 to 9 days pbi.  
The mean clinical score and tracheal titer of E. coli between 0 to 9 days pbi was determined 
for each turkey and used as response variable in a fixed-effects model with the treatment 
group as fixed effect. 
Weight was compared at the end of the trial using a linear fixed effects model with gender and 
treatments as covariates.  
All tests in the fixed-effects model were performed at a global 5% significance level with the 
P-values for the pairwise comparisons adjusted using Tukey’s multiple comparisons 
technique. 
E. coli titers from the turbinates, trachea and lung of the turkeys, euthanized at 6 days pbi 
were compared between the three treatment groups using the Kruskall-Wallis test, whereas 
the presence of E. coli in the airsacs, liver and pericardium of the turkeys, euthanized at 6 
days pbi were compared between the three treatments using the Fisher’s exact test. All these 
tests were performed at a global 5% significance level and the pairwise comparisons were 
tested at an adjusted significance level using Bonferroni’s multiple comparisons technique.  
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Results 
Antimicrobial Uptake 
The actual dose for the single day medication period was 51.3 mg/kg for group E50-
20H. The mean actual daily dose for group E10-5D for the total medication period was 10.2 
mg/kg (range 7.2-11.2 mg/kg). From this we can state that the consumed dose of enrofloxacin 
per group of birds was close to the target dose of 50 mg/kg and 10 mg/kg body weight.  
 
Clinical Signs 
No animals died due to the APV/ E. coli infections. 
The mean clinical scores calculated for each group are presented in Figure 1.  
Signs of upper respiratory distress were seen in all groups starting from 1 day post E. coli 
infection, with the exception of 2 birds from group E10-5D and 1 bird from the control group 
which showed already clear nasal exudates shortly after APV infection.  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 Days post E. coli  inoculation
Clinical score
  
 
Figure 1. Mean clinical scores in turkeys, inoculated with APV followed by E. coli three days later, 
and treated with 10 mg/kg enrofloxacin for 5 days (group E10-5D x) or with 50 mg/kg enrofloxacin 
for 20 hours (group E50-20H ◊). Group C (●) was enclosed as an untreated positive control group. 
Enrofloxacin was administered in the drinking water, 24h after E. coli inoculation.  
 
                 ↑ 
   First treatment day 
  Experimental studies 
___________________________________________________________________________  
 87 
No significant differences between the three groups occurred for the mean clinical score 
between 0 to 6 days pbi (P = 0.1926). For the mean clinical score between 0 to 9 days pbi, 
there is a significant difference between the 3 treatments (P = 0.0064). The control group has 
the highest total score, followed by group E50-20H and group E10-5D. The treatment group 
E10-5D (P = 0.0243) and E50-20H (P = 0.0094) differed significantly from the control group. 
No significant difference was noted between the single and the multiple day treatment (P = 
0.9226). In group E50-20H and group E10-5D the clinical symptoms for any of the animals 
disappeared respectively 5 and 6 days earlier than the control group. 
 
Macroscopic Findings 
The incidence of macroscopic lesions in the different treatment groups is illustrated in 
Table 2. 
Only few macroscopic lesions, limited to the presence of rhinitis in 3 birds, were found in 
group E10-5D. 
Most birds in group E50-20H and in the control group suffered from serous to seromucous 
exudate in the upper respiratory tract and both groups contained birds with lesions in the 
lower respiratory tract. However, the incidence of these lower respiratory tract lesions was 
much higher in the control group, in which three birds with pneumonia and 2 birds with 
airsacculitis lesions were observed. In the single day enrofloxacin treatment group only one 
bird showed lung lesions. 
 
Table 2. Presence of macroscopic lesions at 6 days post bacterial infection (pbi) of turkeys inoculated 
with APV followed by E. coli three days later and treated with a multiple day enrofloxacin dosage 
regimen (10 mg/kg/day for 5 successive days (E10-5D)), a single day enrofloxacin dosage regimen 
(50 mg/kg for 20h (E50-20H)) or no treatment (C) 
Lesion type   C  E50-20H  E10-5D 
rhinitis (nostrils, turbinates)        4/5 (*)   3/5   3/5 
sinusitis   0/5   2/5   0/5 
tracheitis   0/5   0/5   0/5 
pneumonia   3/5   1/5   0/5 
airsacculitis   2/5   0/5   0/5 
       
all respiratory lesions  9/25 (36%)   6/25 (24%)   3/25 (12%) 
 
(*) number of positive observations/total number of observations 
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Necropsy at 15 and 16 days pbi of the remaining birds from the control group showed one 
bird with airsacculitis and another bird with rhinitis and pneumonia. No lesions were found in 
any turkey of the enrofloxacin treatment groups.  
 
Virological  Titration of Tracheal Swabs 
Virological titration of tracheal swabs collected at 2 days post viral infection showed 
that APV was recovered from every bird. Mean titers were 4.6 log10CD50/ml, 4.9 
log10CD50/ml and 4.9 log10CD50/ml for group 10E-5D, group 50E-20H and the control group 
respectively.  
 
Bacteriological Titration of Tracheal Swabs  
The results of the E. coli titrations of the tracheal swabs are shown in Figure 2.  
As from 1 day after bacterial infection, E. coli titers in the control group started to increase, 
resulting in maximal titers of 4.32 log10 cfu/ml at 6 days pbi after which bacterial numbers 
decreased to 0 at 15 days pbi. 
After the first treatment day, i.e. at 2 days pbi, no E. coli was isolated out of any trachea in the 
five day enrofloxacin treatment group for the remaining course of the experiment. The single 
day enrofloxacin treatment highly reduced E. coli multiplication in the tracheae but was not 
able to obtain a permanent clearance of the infection. E. coli titers increased, starting from 4 
days pbi with maximal titers of 1.20 log10 cfu/ml at 6 days pbi, a significantly lower number 
compared to that of the control group. 
There is a significant difference between the three treatments (P < 0.0001) for the mean E. 
coli titers between 0 to 6 days pbi. The two treatment groups differ significantly from the 
control group (P < 0.0001). 
There is also a significant difference between the three treatments (P < 0.0001) for the mean 
E. coli titer between 0 to 9 days pbi. The two treatment groups differ significantly from the 
control group (P < 0.0001). Furthermore, the five day treated group had significantly lower E. 
coli titers than the single day treated group (P = 0.0053). 
Titration of the tracheal swabs on enrofloxacin supplemented agar plates (i.e. 0.25 µg/ml agar 
and 2 µg/ml agar) did not show any growth of less susceptible or resistant E. coli isolates at 
any time during the experiment. 
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Figure 2. Mean E. coli titers in trachea mucus collected at different time points from turkeys, 
inoculated with APV followed by E. coli three days later, treated with 10 mg/kg enrofloxacin for 5 
days (group E10-5D x) or with 50 mg/kg enrofloxacin for 20 hours (group E50-20H ◊). Group C (●) 
was enclosed as an untreated positive control group. Enrofloxacin was administered in the drinking 
water, 24h after E. coli inoculation. 
 
Bacteriological Examination of Tissue Suspensions and Swabs 
E. coli was never isolated from any of the organs of the birds from group E10-5D. 
For the control group and group E50-20H, the various mean E. coli titers in the organs at 6 
days pbi are shown in Table 3. 
Significant differences between treatments were observed for E. coli titers from the turbinates, 
and tracheas. For these organs, the control group showed the highest mean scores, followed 
by group E50-20H and group E10-5D (lowest mean score). For the turbinates, a pairwise 
significant comparison was noted after Bonferroni correction between the control group and 
E10-5D. No pairwise significant differences were noted for E. coli titers of the trachea and no 
significant difference between treatments was noted for the titers of the lungs. 
No E. coli was isolated from the air sacs, pericardium or liver in any bird. 
During the final necropsy, E. coli was discovered in only one lung in a turkey from group 
E50-20H. In the control group, E. coli was isolated 3 times from turbinates, 1 time out from 
airsacs and one time from a trachea. No E. coli was isolated from any turkey of group E10-
                      ↑ 
      First treatment day 
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5D.  No significant difference between treatments was noted for the presence of E. coli in the 
organs during the final necropsy. 
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Weight 
The mean weight gains measured in the after treatment period (i.e. from 1 day before 
E. coli infection until 15 or 16 days pbi) in the different turkey groups are 925 g for the 
control group, 968 g for group E50-20H and 1038 g for group E10-5D. Although no 
significant differences for weight gain are observed between the different groups (P = 0.4749) 
during the after-treatment period, there’s a tendency, showing higher weight gains for longer 
treatment times (group E10-5D>group E50-20H> control group).  
 
 
Discussion 
The five day drinking water medication with enrofloxacin at a dose of 10 mg/kg body 
weight was the most successful in reducing the severity and incidence of the clinical signs and 
macroscopic lesions. E. coli tracheal and organ colonization were limited to the highest 
extent. Less pronounced, although significant, was the outcome of the single day treatment. 
As enrofloxacin exerts a concentration-depending activity (Prescott and Walker, 2000), it was 
hypothesized that higher plasma and respiratory tissue concentrations, due to a higher dosage, 
could succeed in a better killing of the E. coli bacteria. However, the single day treatment 
proved not as efficacious as the five day treatment regimen of 10 mg enrofloxacin/kg body 
weight in reducing E. coli multiplication in the respiratory organs. In contrast to the five day 
treatment, single day treatment did not achieve elimination of E. coli from the respiratory tract 
and the remaining bacteria re-emerged. This indicates that spread of the pathogen to 
susceptible animals could not be avoided using the single day treatment. The duration of the 
treatment at the appropriate dosage seems therefore as important for clinical efficacy as the 
size of the dose. The results obtained in this study, comparing a single and multiple treatment 
regimen, are highly similar to a previously performed study using similar enrofloxacin 
treatment regimens in turkeys infected experimentally with APV and O. rhinotracheale 
(Garmyn et al., in press). Therefore, a single day dosage regimen is not a useful valuable 
alternative to the labelled dosage regimen in treating E. coli associated respiratory disease in 
turkeys and a five day enrofloxacin treatment regimen seems recommended.  
Avian pathogenic E. coli are frequently found to be resistant to commonly used antibacterial 
agents as ampicillin, amoxycillin, tetracyclines, trimethoprim+sulphonamide and flumequine. 
Also, resistance to enrofloxacin is commonly encountered (Vandemaele et al., 2002). 
Acquired quinolone resistance is the consequence of stepwise mutations in the gyr and par 
genes. A first step mutation leads to reduced susceptibility after which successive mutations 
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possibly result in resistance (Barnard and Maxwell, 2001; Hooper, 2001). In this study, 
however, bacterial clones with reduced susceptibility or resistance were not detected in any of 
the enrofloxacin treated groups. Reduced susceptibility or resistance to enrofloxacin also did 
not occur when similar dosing regimens were tested previously on turkeys experimentally 
infected with O. rhinotracheale (Garmyn et al., in press). This supports pharmacokinetic 
findings (Dimitrova et al., 2006; Fraatz et al., 2006) that, when enrofloxacin is used according 
labelled directions, the risk of selection for bacterial resistance is minimized.  
In conclusion, both the multiple and the single day enrofloxacin treatment regimen reduced E. 
coli multiplication in the respiratory tract tissues (turbinates, trachea and lung), but the five 
day treatment with 10 mg enrofloxacin/kg in turkeys provided the best results by shortening 
the course of clinical disease, by eliminating E. coli from the respiratory tract without re-
multiplication, and by reducing macroscopic lesions. The efficacy of the single day treatment 
did not equal that of the 5 day treatment, possibly by not eliminating E. coli from the 
respiratory organs, which made it possible for the remaining bacteria to re-emerge in those 
organs.  
None of the used treatment schemes promoted the selection of bacterial clones with reduced 
susceptibility or resistance. 
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3.3. THE EFFECT OF REDUCED TREATMENT TIME AND DOSAGE OF 
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Summary 
A dose titration and reduced duration medication study were performed to evaluate the 
current enrofloxacin treatment schedule in growing turkeys experimentally infected with 
avian metapneumovirus (APV) and Ornithobacterium rhinotracheale (O. rhinotracheale). 
Experimental groups of 17 four-week-old turkeys were first infected with avian 
metapneumovirus (APV) and three days later with O. rhinotracheale. Enrofloxacin treatment 
in the drinking water was started 24 h after O. rhinotracheale inoculation. In the dose titration 
study enrofloxacin doses of 5, 10 and 20 mg / kg body weight (BW) were administered for 5 
successive days. In the reduced duration medication study, following enrofloxacin regimens 
were compared: 25 mg / kg BW / day on day 0 and day 2, 15 mg / kg BW / day on days 0, 2 
and 4 and 10 mg / kg BW for 5 successive days. In both studies, all enrofloxacin treatments 
were equally efficacious, i.e. equally capable of shortening the course of clinical disease, 
eliminating O. rhinotracheale from the respiratory tract and reducing gross lesions. O. 
rhinotracheale bacteria were not recovered from any of the animals on enrofloxacin 
supplemented media, indicating that none of the used treatment regimens promoted the 
selection of bacterial clones with reduced susceptibility or resistance to this antimicrobial 
agent. In conclusion, none of the alternative enrofloxacin treatment regimens yielded better 
results than the current prescribed treatment (i.e. 10 mg/kg BW for 5 successive days) of O. 
rhinotracheale infections in turkeys. However, the reduced duration of application would 
offer a less time-consuming and equally effective alternative.  
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Introduction 
Respiratory disease induced by various viral and/or bacterial pathogens often affects 
turkeys during the rearing period causing severe economic losses due to growth retardation, 
increased feed conversion rates, increased mortality rates, higher condemnation rates at 
slaughter and high medication costs (van Empel and Hafez, 1999).  
Ornithobacterium rhinotracheale (O. rhinotracheale) plays a significant role in the aetiology 
of the respiratory disease complex (van Empel et al., 1996; Jirjis et al., 2004). Although 
indications of primary pathogenicity exist (Van Veen et al., 2000; Sprenger et al., 1998), the 
organism is mostly regarded as a facultative pathogen, aggravating the symptoms in the 
respiratory tract caused by viruses such as avian metapneumovirus (genus Metapneumovirus) 
(APV) (Van Empel et al., 1996; Jirjis et al., 2004; Marien et al., 2005, 2006). This dual APV/ 
O. rhinotracheale infection frequently occurs in the field (De Rosa et al., 1996; El-Sukhon et 
al., 2002). 
Pursuit of optimal environmental conditions such as good hygiene, adequate ventilation, low 
ammonia levels, optimal relative humidity levels and the prevention of simultaneous 
infections may reduce respiratory disease caused by O. rhinotracheale (van Empel and Hafez, 
1999). In practice, O. rhinotracheale infections are primarily dealt with using antimicrobials 
in the drinking water. Enrofloxacin, a fluoroquinolone antimicrobial compound, is in Europe 
commonly used to cure respiratory infections in turkeys and has proven its efficacy against O. 
rhinotracheale infections, when administered in the drinking water for five successive days at 
a dose of 10 mg/kg body weight (BW), which is the labelled dosage (Marien et al., 2006; 
Marien et al., 2007). This treatment regimen, however, is considered as cumbersome and time 
consuming by many farmers since the medicated drinking water has to be prepared each day 
during five days. This often hinders completion of the full treatment regimen. Other 
controlled clinical studies, addressing enrofloxacin efficacy against O. rhinotracheale 
infections, have not been reported. In addition, acquired resistance or reduced susceptibility of 
O. rhinotracheale against enrofloxacin is commonly encountered (Devriese et al., 1995, 
Malik et al., 2003, Soriano et al., 2003, Van Veen et al., 2000) and more specific data are 
required to search for a therapeutic regimen that minimizes the risk of selecting antimicrobial 
resistant bacteria. In the present study, the efficacy of alternative enrofloxacin treatment 
regimens against O. rhinotracheale infections in experimentally infected turkeys was 
assessed. First the minimum effective dose of enrofloxacin in animals treated during five days 
was determined. In a second study, the efficacy of drinking water treatment with high doses of 
enrofloxacin, administered over a shorter period of time was determined.  
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In both experiments, the selection of O. rhinotracheale clones with reduced susceptibility or 
resistance was also assessed. 
 
 
Materials and Methods 
 
Turkeys 
Commercial turkey poults (Moorgut Kartzfehn, von Kameke GmbH & Co, Bösel, 
Germany) were used in this study. The birds were housed on litter in separate isolation rooms 
with HEPA-filtered air, water and feed were available ad libitum, and received 20 hours of 
light per day. Before bacterial inoculation, tracheal swabs from all birds were examined for 
the presence of O. rhinotracheale and determined to be negative. 
 
Virus 
The APV strain A/T6/96 (subtype A) was used. The strain was isolated during a 
respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998). The virus stock 
had a titre of 105.5 50% ciliostatic dose (CD50)/ml after the third passage in tracheal organ 
cultures.  
 
Bacteria 
The O. rhinotracheale type strain LMG 9086T, originally isolated from a turkey with a 
respiratory tract infection, was used. The strain was serotyped as type A in an agar gel 
precipitation test (Hafez and Sting, 1999), kindly performed by Professor H. M. Hafez 
(Institute of Poultry Diseases, Free University of Berlin, Germany). The minimum inhibitory 
concentration (MIC) of enrofloxacin for the strain was determined at < 0.03 µg/ml and the 
strain was stored at -70°C. The organism was cultured for 48 h at 37°C on Columbia agar 
(Oxoid LTD, Basingstoke, Hampshire, England) with 5% sheep blood in a 5% CO2 
atmosphere. The O. rhinotracheale bacteria were transferred into brain heart infusion (BHI) 
broth (Oxoid) for 24 h at 37°C with agitation. The bacterial challenge inoculum was prepared 
by washing the cultured bacteria twice in phosphate-buffered saline (PBS) followed each time 
by five minutes of centrifugation at 3,000 rpm at 4°C. The resulting pellet was resuspended in 
PBS to obtain a final concentration of 108 colony-forming units (cfu)/ml. Confirmation of the 
number of cfu/ml was done by inoculating ten-fold dilutions in PBS on sheep blood agar and 
counting the number of colonies.  
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Experimental Design 
In a first trial (dose titration study), 85 turkeys were randomly divided into 5 groups 
and inoculated with 104.5 CD50 of APV at 25 days of age. All groups, except group NC, were 
inoculated with 108.5 cfu of O. rhinotracheale, 3 days later. Group NC was enclosed as an 
untreated negative control group. At 24 h after O. rhinotracheale inoculation, 3 groups 
received antimicrobial treatment by medicating the drinking water during 5 successive days. 
The first group received enrofloxacin at 5 mg/kg (group E5-5D), the second group at 10 
mg/kg (group E10-5D) and the third group at 20 mg/kg (group E20-5D).  
In a second trial (reduced duration medication study) 68 turkeys were randomly divided into 4 
groups of 17 animals. At 20 days of age the birds of all groups were inoculated with 104.4 
CD50 of APV and 3 days later with 108.8 cfu of O. rhinotracheale. Three groups received 
enrofloxacin treatment by medicating the drinking water starting at 24 h after O. 
rhinotracheale inoculation. Group E10-5D was treated at a dose of 10 mg / kg BW daily for 5 
successive days. Group E25-2D was treated at a dose of 25 mg / kg BW / day on day 0 and 
day 2 and group E15-3D at a dose of 15 mg / kg BW / day on days 0, 2 and 4.  
In both trials group PC was included as an untreated positive control group. Viral and 
bacterial inoculation occurred by dividing a total of 250 µl of inoculum equally over the 
nostrils and eyes. 
In every group, water uptake was measured on a daily basis from three days before until the 
end of the treatment periods. Additionally, all animals were weighed before O. rhinotracheale 
inoculation. On the basis of these data, the antimicrobial concentrations to be administered in 
the water and the actually received dosages were calculated. Water samples from the 
medicated drinking water were collected daily to determine the actual amount of enrofloxacin 
using turbulent flow chromatography/tandem mass spectrometry (Krebber, 2003).  
All birds were examined for clinical signs on a daily basis throughout the experiment until 
they were sacrificed. The clinical signs of the upper respiratory tract (nasal exudates, swollen 
sinuses, frothy eyes) were scored as described in Van de Zande et al. (2001). The clinical 
condition of each bird was assigned a score from 0 (absence of clinical signs) to 6 (death).  
Tracheal swabs were taken from all birds two days post viral inoculation (pvi) for APV 
enumeration and at regular time points post bacterial inoculation (pbi) for titration of O. 
rhinotracheale. The tracheal swabs were collected using cotton-tipped aluminium shafted 
swabs (Copan Diagnostics Inc., Corona, USA) and placed in transport medium. The latter 
consisted of 1 ml PBS for bacteriological examination which was supplemented with 10% 
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fetal calf serum (Gibco, Invitrogen Corporation, Merelbeke, Belgium), penicillin (1000 U/ml) 
(Biopharma, Rome, Italy) and kanamycin (0.5 mg/ml) (Gibco) for virus enumeration.  
Five birds of each group were sacrificed at 6 days pbi. The birds were necropsied and 
examined for the presence of gross lesions. Samples of the turbinates, trachea and lungs were 
collected and a 10% tissue suspension in PBS was prepared for O. rhinotracheale 
examination. Air sacs, pericardium and liver were sampled with cotton swabs for O. 
rhinotracheale re-isolation.  
Equal numbers of the remaining birds of each group were necropsied and examined for the 
presence of gross lesions at 15 and 16 days pbi (trial 1) or 14 and 15 days pbi (trial 2). 
Turbinates, trachea, lungs, air sacs, liver and pericardium were sampled with cotton swabs for 
O. rhinotracheale re-isolation.  
All samples were processed immediately after collection as described below.   
The birds were weighed the day before the APV inoculation, the day before the O. 
rhinotracheale inoculation and subsequently the final day of the experiment. 
These experiments were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine, Ghent University. 
 
Virological Enumeration and Bacteriological Titration of Tracheal Swabs 
The CD50 per ml of APV and the cfu per ml of O. rhinotracheale were determined, 
using procedures described in Marien et al. (2005). In addition, in order to detect O. 
rhinotracheale isolates with reduced susceptibility to enrofloxacin, samples were also 
inoculated on sheep blood agar supplemented with 5 µg/ml gentamicin, 5 µg/ml polymyxin 
and 0.25 µg or 2 µg enrofloxacin/ml.   
 
Bacteriological Examination of Tissue Suspensions and Swabs 
From samples of the turbinates, trachea, and lungs, the cfu of O. rhinotracheale was 
determined in duplicate by incubating undiluted tissue suspensions and tenfold serial dilutions 
of tissue suspensions on Columbia Blood Agar supplemented with 5 µg/ml gentamicin and 5 
µg/ml polymyxin. After 24-48 h of incubation at 37°C in a 5% CO2 atmosphere, viable counts 
were performed and the number of cfu/ml tissue suspension calculated.  
The swabs taken from the air sacs, pericardium and liver from the 25 birds sacrificed at 6 days 
pbi and the swabs from the turbinates, trachea, lungs, air sacs, pericardium and liver from the 
birds sacrificed at 15 and 16 days pbi (trial 1) or at 14 and 15 days pbi (trial 2) were 
inoculated on Columbia Blood Agar supplemented with 5 µg/ml gentamicin and 5 µg/ml 
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polymyxin. After 24-48 h of incubation at 37°C in a 5% CO2 atmosphere, the agar was 
examined for the presence of O. rhinotracheale colonies.  
 
Statistical Analyses 
Tracheal titres of O. rhinotracheale were analysed for all birds using the 
measurements between 0 and 6 days pbi and subsequently from the birds that were not 
euthanized between 0 and 9 days pbi. The clinical scores and weight were analysed only for 
animals that were not euthanized at 6 days pbi.  
The average over time for the clinical scoring and tracheal swabbing was analysed using a 
fixed-effects model with the treatments group as fixed effect. 
Weight gain was compared at the end of the trial using a fixed-effects model.  
O. rhinotracheale titres from the turbinates, trachea and lung of the birds, euthanized at 6 
days pbi were compared between the five treatment groups with the Kruskall-Wallis test, 
whereas the presence of O. rhinotracheale in the airsacs, liver and pericardium of the animals, 
euthanized at 6 days pbi and the presence of O. rhinotracheale in the turbinates, trachea, 
lungs, airsacs, liver and pericardium of the birds euthanized 15 and 16 days pbi, were 
compared between the five treatments with the Fisher’s exact  test. For the presence of O. 
rhinotracheale in the turbinates at final necropsy also the Chi-Square test was used. 
All tests were performed at a global 5% significance level and the pairwise comparisons were 
tested at a significance level adjusted using Bonferroni’s multiple comparisons technique 
(Agresti, 2002). 
 
 
Results 
 
Antimicrobial Uptake 
Trial 1. Dose Titration Study. The mean actual daily dose for the total medication 
period was 5.36 mg/kg (range 3.9-6.1) for group E5-5D, 10.16 mg/kg (range 9.6-11.7) for 
group E10-5D mg/kg and 20.8 mg/kg (range 18.1-25.8) for group E20-5D.  
Trial 2. Reduced Duration Medication Study. The mean actual daily dose for the total 
medication period was 9.8 mg/kg (range 9.0-10.5) for group E10-5D, 15.5 mg/kg (range 15.0-
16.0) for group E15-3D mg/kg and 24.7 (range 22.0-27.4) for group E25-2D.  
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Clinical Signs 
Trial 1. Dose Titration Study. No animals died due to the APV/O. rhinotracheale 
infections. The mean clinical scores calculated for each group are presented in Figure 1. 
Compared to the positive control group, clinical signs were significantly reduced as well as 
severity and duration in every enrofloxacin treatment group. The negative control group, only 
inoculated with APV, had lower clinical scores compared to all other infected groups at all 
time points.  
Data presented in Table 1 show the area under the curve (AUC) scores from 0 to 9 days pbi. 
The treated groups had significantly lower AUC scores than the positive control (P < 0.037). 
When the three enrofloxacin treatments were compared with each other, no significant 
difference was noted (P > 0.349). All treatments differed significantly from the negative 
control which had higher clinical scores (P < 0.024). 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Days post O. rhinotracheale  inoculation
Clinical score
 
Figure 1. Mean clinical scores in turkeys, inoculated with APV followed by O. rhinotracheale three 
days later, and treated for 5 successive days with 5 mg/kg/day enrofloxacin (group E5-5D ▲), 10 
mg/kg/day enrofloxacin (group E10-5D ◊) or 20 mg/kg/day enrofloxacin (group E20-5D X). The 
positive control group (group PC ■), infected with APV and O. rhinotracheale, and the negative 
control group (group NC ●), infected with APV remained untreated.  
 
Trial 2. Reduced Duration Medication Study. One turkey died in group E25-2D four 
days after the final treatment day, but according to necropsy and bacteriological investigation, 
                        ↑ 
           First treatment day 
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this was due to an Enterococcus faecalis infection.  As no relation to bacterial inoculation or 
study medication was encountered, this turkey was excluded from all statistical analyses. 
 The mean clinical scores calculated for each group are presented in Figure 2. 
Compared to the positive control group clinical signs in the treated groups were less 
pronounced (group E10-5D and E25-2D) or the higher scores reduced over time (group E15-
3D). In addition, clinical signs in the treated groups disappeared two days (group E15-3D and 
group E10-5D) or one day (group E25-2D) earlier, than the clinical scores in the positive 
control group.  
From 7 days pbi onwards, one bird from group E25-2D suffered from an airsac rupture. Since 
no bacterial organism could be isolated out of the airsacs of this turkey during final necropsy, 
this was probably due to trauma.   
Data presented in Table 2 show the AUC scores from 0 to 9 days pbi. Comparisons between 
pairs of O. rhinotracheale infected groups revealed significant differences between group 
E10-5D and the positive control group (P = 0.0085) and also between group E15-3D and the 
positive control group (P = 0.0244).  
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
    Days post O. rhinotracheale  inoculation
Clinical score
 
Figure 2. Mean clinical scores in turkeys, inoculated with APV followed by O. rhinotracheale three 
days later, and treated with 10 mg/kg enrofloxacin for 5 days (group E10-5D ▲), with 25 mg/kg 
enrofloxacin for 2 days alternated with a non treating day (group E25-2D ◊) and with 15 mg/kg 
enrofloxacin for 3 days alternated each time by a non treating day (group E15-3D X). The positive 
control group (group PC ■) remained untreated. 
                         ↑ 
              First treatment day 
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Gross Findings and Lesion Observations 
Trial 1. Dose Titration Study. The observations of gross lesions in the organs of the 
birds necropsied at 6 days pbi and 15 or 16 days pbi are shown in Table 1. Although no 
significant statistical differences between the different groups were noted, the highest 
percentage (48%) of clinically affected organs was seen in the positive control group. This 
group also showed the most severe lesions. Each turkey in the positive control group showed 
mucoserous exudate in the upper respiratory tract (nostrils, turbinates and sinuses) and two 
birds also suffered from airsacculitis. In the other groups, lesions were limited to the upper 
respiratory tract. When the three enrofloxacin treatment groups were compared, fewer birds 
with lesions were seen in group E20-5D (16%) than in group E5-5D (32%) and group E10-5D 
(28%). These latter groups also showed more mucous exudate in the upper respiratory tract 
while the exudate found in birds from group E20-5D was always clear. Comparing E20-5D 
with the negative control group (which was only infected with APV) equal percentages of 
organs affected were found (16%) and gross lesions were relatively similar.  
During final necropsy at 15 and 16 days pbi, three birds from the positive control group and 
one bird from group E5-5D suffered from serous exudate in the upper respiratory tract. One 
bird from the positive control group also showed condensed airsacs. No statistically 
significant difference between the groups could be noted.  
Trial 2. Reduced Duration Medication Study. The observations of gross lesions in the 
organs of the birds necropsied at 6 days pbi and 14 or 15 days pbi are shown in Table 2. 
Most severe lesions and highest percentage of affected organs (60%) were seen in the positive 
control group. Each turkey in this group showed mucous exudate in the upper respiratory tract 
(nostrils, turbinates and sinuses). Four birds also suffered from pneumonia and one from 
airsacculitis. In the treated turkey groups, not every bird was affected.  One turkey from group 
E15-3D and 10E-5D and two turkeys from E25-2D did not show any gross lesions. Lesions in 
the affected birds (serous to mucous exudate) were limited to the upper respiratory tract, 
except for one bird from group E10-5D which showed hyperaemic air sacs. Observations of 
gross lesions in the three enrofloxacin treated groups were highly similar.   
Only a statistical difference was noticed for pneumonia (P = 0.0026 related to the chi-square 
test). Pairwise comparisons with the Fisher’s exact test for each pair of experimental groups 
resulted in significant differences (P = 0.0476) for each comparison of an enrofloxacin 
treatment group to the positive control group. 
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During final necropsy at 14 and 15 days pbi, several birds in every turkey group showed 
congested lungs or an injected pericardium, a side effect of T61 euthanasia. No statistically 
significant results regarding the observations of lesions at the final necropsies could be 
observed between the different turkey groups.  
 
Virological Titration from Tracheal Swabs 
Virological titration of tracheal swabs collected at two days post viral infection, 
showed that APV was recovered from every bird.  
Trial 1. Dose Titration Study. Mean titres were 104.5 CD50/ml, 104.5 CD50/ml, 104.3 
CD50/ml, 104.5 CD50/ml and 104.3 CD50/ml for group E5-5D, group E10-5D, group E20-5D, 
negative control group and the positive control group respectively.  
Trial 2. Reduced Duration Medication Study. Mean titres were 104.3 CD50/ml, 104.5 
CD50/ml, 104.3 CD50/ml and 104.3 CD50/ml for group E10-5D, group E15-3D, group E25-2D 
and the positive control group respectively.  
 
Bacteriological Titration of Tracheal Swabs  
Trial 1. Dose Titration Study. The results of the O. rhinotracheale counts of the 
tracheal swabs are shown in Figure 3. 
 O. rhinotracheale was not isolated at any time during the experiment in the negative 
control group, which was only infected with APV.  
In contrast with the non-treated positive control group, O. rhinotracheale was never isolated 
out of any trachea in any enrofloxacin treatment group after the first treatment day, with the 
exception of group E10-5D, in which O. rhinotracheale was re-isolated occasionally out of 
the trachea of two birds, starting  from five days after the last treatment day (10 days pbi), but 
only at low numbers and without any marked clinical symptoms. 
Using the AUC in the fixed-effects model, all enrofloxacin treatments differed significantly 
from the positive control with lower O. rhinotracheale counts (P < 0.001). There was no 
significant difference between the enrofloxacin treatment regimens (P > 0.18) (Table 3).  
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Figure 3. Mean cfu/ml of O. rhinotracheale in tracheal swabs collected from turkeys, inoculated with 
APV followed by O. rhinotracheale three days later and treated for 5 successive days with 5 
mg/kg/day enrofloxacin (group E5-5D ▲), 10 mg/kg/day enrofloxacin (group E10 -5D ◊) or 20 
mg/kg/day enrofloxacin (group E20-5D X). The positive control group (group PC ■), infected with 
APV and O. rhinotracheale, and the negative control group (group NC ●), infected with APV 
remained untreated.  
 
Trial 2. Reduced Duration Medication Study. The results of the O. rhinotracheale 
counts of the tracheal swabs are shown in Figure 4.  
In contrast with the positive control group, O. rhinotracheale was never isolated out of a 
trachea in any enrofloxacin treatment group after the first treatment day in group E10-5D and 
group E25-2D or after the second treatment day in group E15-3D.   
Using the AUC in a fixed effects-model, all enrofloxacin treatment regimens differed 
significantly from the positive control group (P < 0.0001). There was no significant difference 
between the enrofloxacin treatment regimens (P > 0.05) (Table 4).  
Tracheal swabs were plated on enrofloxacin supplemented agar plates (i.e. 0.25 µg/ml agar 
and 2 µg/ml agar) and did not show any growth of less susceptible or resistant O. 
rhinotracheale isolates at any time during both experiments. 
 
                       ↑ 
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Figure 4. Mean cfu/ml of O. rhinotracheale in tracheal swabs collected from turkeys, inoculated with 
APV followed by O. rhinotracheale three days later and treated with 10 mg/kg enrofloxacin for 5 days 
(group E10-5D ▲), with 25 mg/kg enrofloxacin for 2 days alternated with a non treating day (group 
E25-2D ◊) and 15 mg/kg enrofloxacin for 3 days alternated each time by a non treating day (group 
E15-3D X). The positive control group (group PC ■) remained untreated. 
 
Bacteriological Examination of Tissue Suspensions and Swabs 
             Trial 1. Dose Titration Study. The mean number of cfu/ml of O. rhinotracheale in 
the organs of the birds necropsied at 6 days pbi are shown in Table 3. 
During necropsy at 6 days pbi, O. rhinotracheale was only isolated from the respiratory 
organs (turbinates, trachea, lungs and airsacs) of the positive control group.  
Statistically significant differences were observed for comparison between the enrofloxacin 
treatments and the positive control with lower O. rhinotracheale cfu counts (for air sacs, P < 
0.035; for lungs, P < 0.001; for tracheas, P < 0.001 and for turbinates P < 0.001) in the treated 
groups. There was no statistically significant difference between the enrofloxacin treatment 
regimens. 
 
 
 
                           ↑ 
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During necropsy days 15 and 16 days pbi, one turkey belonging to group 10E-5D, showed 
presence of O. rhinotracheale in the turbinates and two turkeys from the same groups in the 
turbinates and in the trachea. These were the same birds in which O. rhinotracheale was re-
isolated from the tracheal swabs, five days after the final treatment day. O. rhinotracheale 
was not isolated from any other organ in any other bird. In the trachea, the difference between 
treatments was not statistically significant (P > 0.1). In the turbinates, the Chi-Square test 
concluded in significant differences between treatments (P = 0.022) while the Fisher exact test 
was statistically borderline (P = 0.051). 
Trial 2. Reduced Duration Medication Study. The mean number of cfu/ml of O. 
rhinotracheale in the organs at 6 days pbi are shown in Table 4. 
During first necropsy 6 days pbi, O. rhinotracheale was also only isolated out of the 
respiratory organs (turbinates, trachea, lungs and airsacs) from the positive control group.  
Statistically significant differences regarding the O. rhinotracheale titres in the turbinates, 
trachea and lungs were observed for all comparisons of the three enrofloxacin treatment 
groups to the positive control group (for every comparison P = 0.0079). For these organs 
(turbinates, trachea and lungs), no statistical differences were observed between the three 
enrofloxacin treatment regimens. Also no statistical differences were observed between the 
four experimental groups regarding the presence of O. rhinotracheale in the airsacs, pericard 
and liver. 
During final necropsy, O. rhinotracheale could not be isolated out of any organ.  
 
Weight 
During both trials, no global treatment effect on weight gain could be observed. In trial 
1 the positive control group showed the lowest weight gain and there was one single 
significant pairwise difference for the 81 g higher weight gain observed in E10-5D compared 
to the positive control group (P = 0.0495). In trial 2 group E15-3D showed the highest weight 
gain. However, again this difference was not statistically significant 
 
 
Discussion 
The infection model used in these experiments was based on a model developed by 
Marien et al. (2005) for the reproduction of infectious respiratory disease in turkeys. Since the 
results obtained in the control groups in both experiments are very similar to their findings, 
the infection model appears to be highly reproducible.   
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Regarding the clinical symptoms in the dose titration study (trial 1), the negative control 
group scored statistically significant better than the other groups. This was expected since the 
negative control group was only infected with APV. It is generally acknowledged that O. 
rhinotracheale exerts a synergistic effect on APV infections in turkeys by aggravating the 
symptoms encountered in the respiratory tract (Van Empel et al., 1996; Jirjis et al., 2004, 
Marien et al., 2005). Looking at the clinical scores and the respiratory lesions observed during 
necropsy in the positive and negative control group, this experiment (trial 1) confirms these 
findings.  
Taking in consideration that, compared to the negative control group, the course of clinical 
disease in the enrofloxacin treated groups in the dose titration study (trial 1) was only 
prolonged for a day and that no significant differences could be noted for the gross lesions 
encountered during necropsy, it can be suggested that the viral multiplication of APV had a 
major impact on the overt respiratory symptoms in the three enrofloxacin treated groups. In 
the APV/ O. rhinotracheale infected, untreated birds, however, clinical disease was more 
severe. Thus, the multiple day enrofloxacin treatments were able to eliminate most of the O. 
rhinotracheale associated aggravation of the APV infection.  
Statistical analysis confirms these findings as each enrofloxacin treatment regimen, used in 
trial 1, showed statistically significant better results for most parameters examined, compared 
to the APV/O. rhinotracheale infected, untreated positive control group (i.e. clinical scoring, 
O. rhinotracheale titres from tracheal swabs and O. rhinotracheale titres from organs 6 days 
pbi). Comparable results were observed in the reduced duration medication study (trial 2). 
Here also with every enrofloxacin treatment statistically significant better results were 
obtained regarding clinical score (with the exception of the group treated with 25 mg/kg for 
two days, although capable of limiting the clinical symptoms and shortening the course of 
respiratory disease), the O. rhinotracheale titres in the tracheas, the O. rhinotracheale counts 
in the organs and the observations of pneumonia at necropsy 6 days pbi, compared to the 
positive control group. As no adverse reactions were observed the reduced duration 
medication was apparently well tolerated. However the alternative medication regimens with 
higher daily doses at fewer medication days could affect the drug depletion period and 
subsequent withdrawal time. 
Both in the dose titration study and in the reduced duration medication study no statistical 
differences could be noted between the different enrofloxacin treatments. Every enrofloxacin 
regimen resulted, in both trials, in an equal reduction of clinical signs and equal shortening of 
the course of respiratory disease. Moreover, all regimens were able to eliminate the O. 
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rhinotracheale infection from the diseased turkeys since no O. rhinotracheale bacteria could 
be isolated out of any trachea or organ after the first treatment day. Such clearance of O. 
rhinotracheale could not be obtained after the administration of a single day dose of 50 mg/kg 
which resulted in the re-emergence of the bacterium after treatment (Garmyn et al., 2009). 
Re-emergence was not observed when the 50 mg/kg dose was split over a two or three day 
period. 
Overall, for the treatment of O. rhinotracheale infections with an enrofloxacin sensitive 
strain, a five day treatment regimen of 20 mg enrofloxacin/kg was not shown to be more 
efficacious than the labelled dosage (10 mg enrofloxacin/kg daily for 5 days) and a five day 
treatment regimen of 5 mg enrofloxacin/kg was found equally efficient as the labelled dosage. 
Whether under field circumstances, with frequent O. rhinotracheale/ E. coli mixed infections 
involved in turkey respiratory disease, clinical disease  could be controlled with the 5 mg/kg 
regimen remains to be determined. The labelled dosage for enrofloxacin for respiratory 
colibacillosis is 10 mg/kg BW. Also reduced duration medication could be a valuable 
alternative to the labelled dosage against O. rhinotracheale infections in turkeys, providing 
that the total administered dose (50 mg/kg) is complied with i.e. 2 times 25 mg/kg or 3 times 
15 mg/kg, alternated each time by a day without treatment. This would improve user 
convenience by reducing the workload for the farmer who will only have to prepare 
medicated water for two or three days instead of five. In a previous study performed by 
Marien et al. (2006) an enrofloxacin drinking water treatment of 3 or 5 continuous days 
showed to be equally effective. The results obtained in this study suggest that every other day 
treatment with enrofloxacin would seem to be of value. Hence, it is demonstrated that when 
enrofloxacin is used in the drinking water, a flexible adaptation of the duration of treatment, 
depending on the evolution of the respiratory disease in the stable, is possible.  
Five days after the final enrofloxacin administration in the dose titration study (trial 1), low 
titres of O. rhinotracheale were isolated out of two birds from the group receiving 10 mg 
enrofloxacin/kg daily for 5 days. This tracheal re-colonization, several days after the final 
treatment day, was not seen in the lower and higher dose group, and is expected not to be dose 
dependent. It is reported that O. rhinotracheale can survive for several days in the 
environment (Lopes et al., 2002). Therefore this re-excretion or re-infection, which was not 
accompanied by clinical relapse, is likely just incidental.  
Acquired resistance to enrofloxacin is commonly encountered in O. rhinotracheale (Devriese 
et al., 1995; Malik et al., 2003) and is the consequence of stepwise mutations in the gyr and 
par genes (Barnard and Maxwell, 2001; Hooper, 2001). In these studies, however, O. 
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rhinotracheale clones with reduced susceptibility or resistance were not detected in any of the 
enrofloxacin treatment groups.  
In conclusion, the enrofloxacin treatments tested in the dose titration study (5, 10 or 20 mg 
enrofloxacin/kg, daily for 5 days) and the reduced duration medication study (2 x 25 mg 
enrofloxacin/kg, 3 x 15 mg enrofloxacin/kg, alternated each time by a day without treatment 
and 10 mg enrofloxacin/kg, daily for 5 days) were equally capable of shortening the course of 
clinical disease, eliminating O. rhinotracheale from the respiratory tract and reducing gross 
lesions. Since little differences could be observed for the clinical scores and the gross lesions, 
when the enrofloxacin treatment groups and the negative control group were compared, the 
viral multiplication of APV had a major impact on the overt respiratory disease symptoms in 
all experimental groups. However, all multiple day enrofloxacin treatments were able to 
eliminate most of the O. rhinotracheale associated aggravation of the APV infection, which 
resulted in more severe and long-lasting respiratory symptoms in the non treated positive 
control group. 
As no O. rhinotracheale bacteria grew on the enrofloxacin supplemented media, none of the 
used treatment regimens promoted the selection of bacterial clones with reduced susceptibility 
or resistance.  
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 GENERAL DISCUSSION 
 
Antimicrobial use in poultry production: a hot and controversial topic 
Antimicrobial use in the poultry industry is currently under scrutiny. Emerging 
antimicrobial resistance is becoming an increasing problem in most bacterial species. For O. 
rhinotracheale reduced susceptibility or resistance have been reported against amoxicillin, 
ampicillin, doxycycline, enrofloxacin, flumequine, gentamicin, lincomycin, trimethoprim-
sulfonamide, tetracycline and tylosin (Van Empel and Hafez, 1999; Devriese et al., 2001; van 
Veen et al., 2001; Malik et al., 2003; Soriano et al., 2003). Avian pathogenic E. coli are 
frequently (multi-)resistant to tetracyclines, sulfonamides, ampicillin, and streptomycin 
(Barnes et al., 2008), but also for other antimicrobials commonly used in the poultry industry 
reports of reduced susceptibility or resistance exist (Cormican et al., 2001; Altekruse et al., 
2002; Barnes et al., 2008). For both bacterial species susceptibility may depend on the regime 
used by the poultry industry in various geographical locations (Barnes et al., 2008). 
Concerns are also growing about antimicrobial resistance in bacteria from food animals, and 
their impact on human health. These resistant strains may be zoonotic, but also resistant 
commensals pose a hazard, since they can transfer their resistance genes to human pathogens. 
Heated discussions regarding the degree of risk this hazard poses, have been and are still 
being held between those who are very concerned about the risk (Witte, 1998) and those who 
believe that the evidence for a substantial risk remains sparse (Phillips et al., 2004). 
Many risk assessments have been conducted, but in many cases the results were impended by 
shortage of suitable data sets (Snary et al., 2004). In addition, a number of countries have 
incorporated surveillance programs, e.g. National Antimicrobial Resistance Monitoring 
System (NARMS), European Antimicrobial Susceptibility Surveillance in Animals (EASSA) 
or Danish Integrated Antimicrobial Resistance Monitoring and Research Programme 
(DANMAP), but these monitoring programs do not yet provide adequate information 
regarding the risk of antimicrobial resistance, which is therapeutic failure due to a specific 
drug resistance in humans (Mathew, 2007).  Although no definite conclusion has come from 
the several meetings designed to discuss the question of antimicrobial resistance and the use 
of antibiotics in poultry, the controversy has led to legislative changes affecting the 
availability of antimicrobials approved for use in poultry. From September 2005, the US Food 
and Drug Administration banned the use of enrofloxacin in poultry farms in the USA (not in 
Europe) as it was expected to jeopardize human health through the emergence of 
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fluoroquinolone-resistant strains of Campylobacter in enrofloxacin medicated poultry (FDA, 
2005). Since January 2006, the water -or feed- based administration of antimicrobials to 
animals as growth promoters has been completely banned in the European Community as 
such use has been shown to contribute to the increased prevalence of antimicrobial-resistant 
bacteria of human significance (e.g. enterococci). It is certainly true that the widespread 
practice of mass dosing antimicrobials in the drinking water, using sub-therapeutic levels 
promotes the emergence of resistance (Iovine and Blaser, 2005; Johnsen et al., 2009). It is 
also true that removal of the selective pressure by abolishing the use of a certain antimicrobial 
can reduce the frequency of resistance (Han et al., 2009; Johnsen et al., 2009). However, 
complete reversal of acquired drug resistance in bacterial populations that were no longer 
exposed to a specific antimicrobial drug has never been reported (Sepala et al., 1997; Enne et 
al., 2001; Sorum et al., 2006; Price et al., 2007) and any use of antimicrobial drug may 
eventually lead to resistance. Redundant use of antimicrobials should certainly be avoided and 
the use of antimicrobials should certainly not be a crowning piece of disease control 
programmes. Yet, a ban of the use of an antimicrobial product has implications for animal 
welfare by limiting efficacious drugs to treat disease. Therapeutic applications of 
antimicrobials are vital for profitable and livestock production, essential for animal welfare 
and minimizing economic losses (McMullin, 2004). To retain the efficacy of antimicrobial 
drugs currently available for the control of bacterial infections, prescription and 
administration of antimicrobial agents should be undertaken with discretion, supported by an 
accurate diagnosis and a careful choice of the respective substance(s) (Schwarz et al., 2001).  
 
Efficacy of the labelled enrofloxacin regimen  
The principal goal of therapeutic antimicrobial use in poultry is maximum eradication 
of the pathogen as quickly as possible with minimal adverse effects on the recipient and 
prevention of the emergence of resistant organisms (Tanner et al., 2003).  
Currently, enrofloxacin is the most potent antimicrobial drug so far used for respiratory 
infections in poultry medicine. From all fluoroquinolone antimicrobials which are approved 
for poultry use, enrofloxacin shows the highest in vitro activities against avian respiratory 
pathogens (Pirro, 1997; Norcia et al., 1999, Fraatz et al., 2002; Himmler et al., 2002; Miller 
et al., 2005). Administered in the drinking water at 10 mg/kg for 5 successive days (the 
currently labelled dose) enrofloxacin proved efficacious against any bacteria playing a 
significant role in turkey respiratory disease (Braunius, 1987; Behr et al., 1988; Hafez et al., 
1992; Cargill, 1995; Gautrais and Copeland, 1997; Marien et al., 2006). During this research, 
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the efficacy of this treatment against respiratory disease in turkeys caused by APV/O. 
rhinotracheale or APV/E. coli infections has been endorsed. In every study, E coli or O. 
rhinotracheale was rapidly eradicated from the respiratory tract. Already one day after onset 
of treatment, neither E. coli nor O. rhinotracheale could be isolated out of the trachea. When 
turkeys were necropsied immediately after the final treatment day, the respective pathogens 
were never cultured from the internal organs. The course of respiratory disease was shortened 
with several days and clinical signs and gross lesions were less severe than those observed in 
non-treated, E. coli or O. rhinotracheale infected control groups. It might even be assumed 
that most of the clinical signs observed originated from the APV inoculation, which was used 
to trigger the bacterial infections.  
Considering PK/PD parameters, the clinical and bacterial outcome of this treatment regimen 
was expected. Fraatz et al. (2006) observed that after continuous drinking medication at a 
dose of 10 mg/kg body weight in turkeys, steady state serum concentrations of enrofloxacin 
ranged between 0.32-0.45 µg/ml. In the respiratory tract, concentrations were even 2 times 
higher. These concentrations exceed MIC90 values for E. coli (0.06 µg/ml) by approximately 
four log2 and for O. rhinotracheale (0.25 µg/ml) by two steps (Fraatz et al., 2006). A single 
oral dose PK study with 10 mg/kg BW enrofloxacin resulted in mean Cmax values of 1.89 
µg/ml and mean AUC0→24 values of 18.1 h.g/ml (Fraatz, 2006, data on file). Dimitrova et al. 
(2007) observed Cmax/MIC ratios from 161.23 h to 12.90 h and AUC0→24/MIC ratios from 
2153.44 h to 137.82 h for clinically significant micro-organisms whose MIC varied from 
0.008 µg/ ml to 0.125 µg/ml (10 mg/kg BW). Although in the latter study, enrofloxacin was 
given in a pulsed manner, continuous drinking water treatment is believed to reach similar 
AUC levels (Stegeman, 1995). Based on the above, a treatment regimen of 10 mg/kg 
enrofloxacin for 5 continuous days against strains of O. rhinotracheale and E. coli with MIC 
of 0.03 µg/ml, should be sufficient to reach Cmax/MIC ratios >10 and AUC0→24/MIC ratios 
>100-125. These ratios are associated with maximal clinical and microbiological effects in 
Gram-negative bacteria (Blaser et al., 1987; Madaras-Kelly et al., 1996, Frimodt-Moller, 
2002).  
 
The dosage of enrofloxacin: time for change? 
The dose titration study, administering 5 mg enrofloxacin/kg BW instead of 10 mg/kg 
BW, continuously in the drinking water for five successive days proved equally effective as 
the enrofloxacin treatment of 10 mg/kg BW for five continuous days against susceptible O. 
rhinotracheale infections in turkeys (MIC 0.03 µg/ml). Here also, efficacy could have been 
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predicted. A pharmacokinetic study performed in chickens by Reinhardt et al. (2005) in which 
enrofloxacin concentrations in serum samples were determined after administration of 
increasing doses of enrofloxacin against Mycoplasma gallisepticum, showed that serum 
concentrations of enrofloxacin are directly proportional to the rate of absorption, which, in 
turn, is dependent on the concentration at the absorption site. In theory, based on previous 
Cmax/MIC ratios and AUC0→24/MIC ratios, even half the concentration of enrofloxacin in the 
plasma and respiratory tissues are considered adequate for clinical and microbiological 
effectiveness against susceptible O. rhinotracheale isolates. In the field usually mixed 
infections occur and first step mutants may be involved in the infection. Still, the efficacy of 
the 5 mg enrofloxacin/kg BW treatment has not been established against other bacterial 
respiratory pathogens or less susceptible O. rhinotracheale isolates. Hence, it would be 
advisable to use the 10 mg/kg treatment in respiratory disease outbreaks in the field. Despite 
their efficacy, previous treatment regimens are considered as cumbersome and time 
consuming by poultry breeders. Since enrofloxacin is a photosensitive molecule (Sumano et 
al., 2004) the medicated drinking water has to be prepared each day during five days. And, 
because of the resistance problem associated with this class of antimicrobials, the use of 
enrofloxacin and other fluoroquinolones in the poultry industry is currently under scrutiny. 
Although during this entire research period, less susceptible or resistant E. coli or O. 
rhinotracheale isolates were never encountered after enrofloxacin treatments of 10 mg/kg BW 
administered for 5 successive days, other investigators did (Barrow et al., 1998, Marien et al., 
2006a). Isolates with reduced susceptibility or even resistance to fluoroquinolone have also 
been reported in Campylobacter sp. (McDermott et al., 2002, Luo et al., 2003, Van Boven et 
al., 2003) and Salmonella sp. (Barrow et al., 1998; Randall et al., 2005; 2006), even after 
single administration of the labelled regimen.  
Previous dosing strategies have been designed according PK/PD parameters based on MICs. 
MIC values, however, refer to drug susceptible populations and are therefore not relevant to 
the prevention of growth of resistance mutants (Firsov et al., 2003; Drlica and Zhao, 2007). In 
wild type cells, spontaneous mutations in DNA arise at frequencies varying from one in 106 to 
one in 109. For MIC measurements, inocula only contain 104 cfu (Andrews, 2001). In such 
relatively small bacterial populations, the occurrence of mutant bacterial isolates is unlikely. 
However, in diseased animals bacterial populations are more likely the size of 107 and 108 cfu. 
Therefore, at the site of infection, bacterial variants with reduced drug susceptibility to 
enrofloxacin (first-step mutants) will be most likely present (Pourkbahsh et al., 1997; Sanders, 
2001; Drlica and Malik, 2003; Wetzstein, 2005). Recently the concept of the mutant selection 
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window hypothesis (Zhao and Drlica, 2008) has found quite some support. The upper 
boundary of the window, called the mutant prevention concentration (MPC) defines a drug 
threshold at which visible re-growth from a bacterial population compromising 109 to 1010 cfu 
is completely inhibited. Therefore, the heterogenity in sensitivity of the bacterial population at 
the infection site, which remains undetected in MIC testing, is revealed in MPC curves 
(Wetzstein, 2005). When a drug falls below the MPC into the so called mutant selection 
window (of which the lower limit can be approximated by MIC) selection pressure exerted by 
fluoroquinolone treatment will enrich mutant subpopulations (first step mutants) (Sanders, 
2001; Drlica and Malik, 2003; Blondeau et al., 2004). On the other hand, maintaining drug 
concentrations above the selection window throughout therapy should severely restrict the 
acquisition of drug resistance. To grow above the MPC, a bacterial isolate would require > 2 
concurrent mutations. Since this happens at frequencies of one in 10-14 cells, this would be 
very unlikely (Blondeau et al., 2004). MIC is said to define the sensitivity of the first target. 
MPC on the other hand defines the sensitivity of the secondary fluoroquinole targets 
(Wetzstein, 2005). 
Resistance to fluoroquinolones arises almost exclusively by de novo mutations and is the 
consequence of gradual accumulation of mutations in the target genes. A first step mutation 
usually only leads to reduced susceptibility which is regarded as clinically irrelevant (Hooper, 
2001; Andriole, 2003). However, when such less susceptible isolates survive in the 
environment, the MIC of bacterial populations may increase stepwise. Eventually, only 1 
additional mutation will be needed before resistance occurs (Schentag et al., 2003). Therefore 
the selection of less susceptible isolates should be avoided by maintaining drug concentrations 
above the MPC throughout therapy.  To determine whether MPC can be clinically applied, it 
must be measured for relevant bacterial populations. To be useful, the MPC should be within 
the concentration limits that can be safely reached in patients.  
The possibility has been raised that MPC might be a fixed multiple of MIC (Sanders, 2001). If 
so, MPC could be determined from MIC measurements. However MPC and MICs correlate 
poorly (Drlica et al., 2006). For enrofloxacin, MPC’s have only been reported for a few 
pathogens (Etienne et al., 2004; Wetzstein, 2005). For wildtype E. coli populations (MIC 
0.03), wildtype E. coli WT (MIC 0.06) and E. coli ATCC 25922 (MIC 0.03), the MPC for 
enrofloxacin were respectively 0.3-0.35 µg/ml, 0.4-0.5 µg/ml, and 0.15-0.175 µg/ml 
(Wetzstein, 2005). Since values for O. rhinotracheale were not described, the provisional 
MPC of the O. rhinotracheale strain (MIC 0.03 µg/ml) was determined following Blondeau 
(2001).  For this, starter cultures were spread on blood agar plates and incubated 48h at 37°C 
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in 5% CO2. Bacterial cells were then transferred from the plates to 500 ml BHI broth (Oxoid) 
followed by overnight incubation at 37°C in 5% CO2. After incubation, cultures were 
estimated to have concentrations of > 3 x 108 cfu/ml by turbidity measurements. Cultures 
were concentrated by centrifugation at 5.000 x g for 10 min and resuspended in 3 ml of PBS. 
Aliquots of 200 µl, containing > 1010cfu, were applied to Muller Hinton II agar (Oxoid) 
dilution plates containing 5% defibrinated horse blood. Agar dilution plates were freshly 
prepared by incorporating enrofloxacin at thirteen concentrations and dilutions of 
enrofloxacin (1x to 128x MIC). The fully susceptible LMG ORT strain was included as 
control. Inoculated plates were incubated for 48h at 37°C in 5%CO2 and then screened for 
growth. All plates were re-incubated for an additional 24h and re-examined. MPC was 
recorded as the lowest antibiotic concentration that allowed no growth. The provisional MPC 
of O. rhinotracheale measured 2 µg/ml. Since the provisional MPC overestimates MPC by 
about twofold (Blondeau et al. 2001), the MPC value of this O. rhinotracheale strain is 1 
µg/ml. Determinations were made in duplicate, and the results were identical. After 
continuous drinking medication at a dose of 10 mg/kg body weight in turkeys, steady state 
serum concentrations of enrofloxacin only ranged between 0.32-0.45 µg/ml (Fraatz et al., 
2006). According to the concept of the mutant selection window hypothesis the labelled 
treatment should not prevent the selection of first step mutations in the O. rhinotracheale 
strains used in this research since enrofloxacin concentrations are too low to exceed O. 
rhinotracheales MPC. Therefore, the treatment regimen in which enrofloxacin was 
administered at 20 mg/kg BW for 5 successive days, probably better reduces the selection of 
less susceptible or resistant microbial subpopulations of O. rhinotracheale. The increased 
(doubled) steady-state concentrations in serum and tissues should offer improved conditions 
maintaining drug concentrations above the selection window throughout therapy. Application 
of this dosing strategy is, however, not completely straightforward. A five day treatment at 20 
mg/kg BW/daily proved only to be equally efficacious as the current labelled dose against O. 
rhinotracheale infections. Improved clinical effect or better bacterial eradication was not 
noticed. This suggests that drug concentrations in the body were probably higher than 
necessary for clinical cure against susceptible O. rhinotracheale infections. On the other hand, 
increasing the daily drug dose also means an increase of the treatment cost. In addition, 
treatment would be still as labour-intensive as the “traditional” labelled dosage regimen.  
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Rethinking the treatment duration for improved treatment efficacy 
To deal with these inconveniences, it was hypothesized that reduced duration therapies 
could offer a solution. For drugs like enrofloxacin with concentration dependent killing 
activity higher peak drug concentration in serum and tissues ensure better bacterial 
eradication and clinical effect, reducing the time needed to treat (Frimodt-Moller, 2002). 
Therefore administering higher doses of fluoroquinolones might shorten the course of 
treatment while efficacy is maintained and in the meanwhile the development of resistance in 
bacteria is reduced (Drusano et al., 1993; Forrest et al., 1993; Meinen et al., 1995, Scaglione 
et al., 2003, Randall et al., 2006). However, observations made during this research presume 
that, for an optimal antimicrobial effect, dosing strategies do not only seem to confer 
appropriate drug concentrations but also an appropriate time of exposure for the target 
pathogen. Although it has been frequently stated that the antibacterial effects of enrofloxacin 
at the clinical level are more dependent upon a higher peak in serum concentrations than an 
extended residence time (Puyt, 1995; Brown, 1996, Riviere, 1999; Sumano and Gutierrez, 
2000) the exposure time of enrofloxacin achieved after single day dosing for the treatment of 
APV/E. coli and APV/O. rhinotracheale infections was found too short. 
Providing the same total dose of 50 mg enrofloxacin /kg BW administered in 5, 10 or 20h 
proved not to be equally efficacious as the labelled regimen of 10 mg/kg BW for 5 successive 
days. Although respiratory disease was reduced in time and severity, the clinical and 
antimicrobial effects of the single day regimens did not match those of the labelled treatment 
regimen. Moreover, O. rhinotracheale and E. coli were not completely eradicated from the 
turkey’s respiratory tract, since the pathogens rapidly re-emerged after treatment. Since it is 
implicit for an optimal dosing strategy that the offending pathogen is eradicated (Tanner, 
2003; McKellar et al, 2004) single day treatment regimens are not considered a valuable 
alternative to the labelled dose. Deplorable, since Randall et al. (2006) reported that a single 
dose of 50 mg enrofloxacin/kg BW in chickens experimentally infected with Salmonella 
enterica might evidence for a decreased selection of less susceptible isolates.  
The higher Cmax achieved with single day dosing, hypothesized to be advantageous compared 
to the continuous dosing, did not result in improved efficacy against E. coli and O. 
rhinotracheale infections in turkeys. Previously, studies comparing pulse enrofloxacin dosing 
(i.e. administration of the daily dosis enrofloxacin in two to four hour period) and continuous 
enrofloxacin dosing (administering enrofloxacin in the drinking water over a 24-h period) 
came to similar observations. In these studies also, higher peak concentrations associated with 
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pulse dosing were not linked to improved clinical efficacy (Stegeman, 1995; Charleston, 
1998; Froyman and Cooper, 2003).  
Drug exposure time proved appropriate when the total dose of 50 mg/kg dose was split over 
two or three days i.e. 2 times 25 mg/kg or 3 times 15 mg/kg, alternated each time by a day 
without treatment. Both reduced duration medications proved equally efficacious as the 
labelled regimen in reducing clinical signs, shortening the course of respiratory disease ànd 
eradicating the target pathogen, e.g. O. rhinotracheale. Comparable dosing regimens, splitting 
the total dose of 50 mg fluoroquinolone/kg BW over 2 or 3 days, tested in humans and 
chickens against Salmonella infections proved also equally efficacious as a 5 day treatment at 
10 mg/kg (Hien et al., 1995; Randall et al., 2006). Although only equal and not improved 
clinical and antimicrobial efficacies were observed - compared to the current labelled 
treatment regimen - it is believed that these reduced duration medication regimens might have 
additional advantages. Since the course of treatment is shortened, medicated drinking water 
will only have to be prepared two or three times instead of five, which is less-time consuming 
for the turkey breeder. In addition, a regimen of 2 x 25 mg enrofloxacin/kg BW alternated 
with a non treating day could result overall in a shorter withholding time. Furthermore, the 
higher peak plasma and respiratory tissue concentrations, resulting from the higher dosages 
might offer better conditions for restricting selection of less susceptible isolates than the 
current treatment schedule. This is evidenced by Randall et al. (2006), who observed less 
isolates of Salmonella enterica with reduced susceptibility after a 2-day treatment at a dose of 
25 mg/kg than after a five day treatment of 10 mg/kg. Therefore, reducing the treatment 
period against O. rhinotracheale infections in turkeys might reduce the rate at which less 
susceptible O. rhinotracheale isolates appear. It is also important to emphasize that the total 
enrofloxacin dose, compared to current labelled doses, administered was unaltered. Hence, the 
medication cost is not increased. Therefore, reduced duration medications providing 2 x 25 
mg enrofloxacin/kg or 3 x 15 mg enrofloxacin/kg, alternated each time by a day without 
treatment might be considered as valuable dosing regimens against O. rhinotracheale 
infections in turkeys.  
 
Considerations regarding the safety of the modified regimens, their traits to reduce the 
emergence of resistance and the used challenge model 
Enrofloxacin is regarded as a safe antimicrobial (Anonymous, 2003). In poultry, side-
effects have never been observed after administering the registered treatment dose.  However, 
when (daily) antimicrobial drug doses are increased, the risk exists that these higher drug 
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concentrations might induce toxic effects. Toxic signs sometimes associated with very high 
enrofloxacin doses in poultry are gastrointestinal disturbances and in one single case 
arthropathies caused by cartilage lesions have been observed in the past (Walker, 2000). 
Nevertheless, such symptoms or other adverse events were not observed in any turkey during 
the studies performed for this research whenever (daily) increased enrofloxacin doses (higher 
than the labelled 10 mg/kg BW) were administered. Therefore, every treatment regimen tested 
may be considered safe.  
During treatment every enrofloxacin regimen was checked for selection of less-
susceptible or enrofloxacin resistant O. rhinotracheale or E. coli isolates. Since neither the 
current labelled dosage nor any modified regimen ever promoted the selection of such less 
susceptible or resistant isolates, it is difficult to conclude if the presumed improved 
pharmacokinetics and pharmacodynamics of certain modified enrofloxacin regimens (20 
mg/kg for five continuous days and the alternative day- reduced duration medications) really 
reduce emergence of less susceptible or resistant strains than the currently labelled dosis. 
Applying these regimens in field studies enclosing larger number of birds could result in more 
conclusive evidence.  
When the efficacies of different treatment regimens against a specific disease are to be 
compared, it is of extreme importance to use a highly reproducible challenge model. If not, it 
would not be clear whether the differences in clinical and antimicrobial outcome between 
different treatment groups are due to the impact of the treatment in se or whether they are the 
result of external factors. This holds true, especially for reproducing a disease as complex as 
respiratory disease in poultry of which the course and the severity of clinical signs can be 
influenced by many different environmental factors (Kleven, 2008). Only very recently, 
Marien (2008) succeeded in the development of such infection model that can reproduce 
respiratory disease caused by respiratory pathogens currently considered significant in the 
turkey industry (i.e. APV, E. coli, O. rhinotracheale, and Mycoplasma). Marien et al. (2006) 
used this infection model to compare the efficacy of different classes of antimicrobials.  
Present research shows that the model also proves extremely valuable to compare efficacies of 
different treatment regimens, since in the currently performed O. rhinotracheale trials 
equivalent results are observed when the clinical scores (Figure 1) and the tracheal titres 
(Figure 2) of the different  positive control groups are compared to each other. 
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Figure 1. Mean clinical scores in turkeys belonging to the positive control group (i.e. inoculated with 
APV and three days later with O. rhinotracheale without successive enrofloxacin treatment) during 
the single day treatment study (♦), the dose titration study (■) and the reduced duration medication 
study (▲).  
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Figure 2. Mean tracheal titres in turkeys belonging to the positive control group (i.e. inoculated with 
APV and three days later with O. rhinotracheale without successive enrofloxacin treatment) during 
the single day treatment study (♦), the dose titration study (■) and the reduced duration medication 
study (▲).  
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Conclusion and recommendations for further research 
Overall, the current labelled treatment regimen proves very efficacious against 
respiratory disease caused by susceptible O. rhinotracheale and E. coli strains and did not 
promote the selection of less susceptible or resistant isolates in any study performed during 
this research. Although not clinically more efficient, certain modified regimens tested, e.g. the 
alternative day-reduced duration medications could offer a valuable alternative.  
However, further work is needed to ascertain how effective these modified treatment 
regimens are against other bacterial respiratory pathogens not included in this research or 
mixed bacterial respiratory infections. It would also be interesting to look at the effect of these 
higher enrofloxacin treatment levels on the gut microbiota, since the selection of resistant 
mutants during antimicrobial treatment may not only take place at the site of infection but at 
any bacterial population resident in the body. Furthermore, since evidence exists that less 
susceptible enrofloxacin isolates are not as clinically irrelevant as primarily thought, it would 
be useful to test the efficacy of labelled dosage and modified regimens against first step 
mutants of O. rhinotracheale or E. coli. 
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SUMMARY 
 
Respiratory disease on turkey farms world-wide leads to economic losses due to 
growth retardation, increased feed conversion rates, increased mortality rates, higher 
condemnation rates at slaughter and high medication costs. Bacterial pathogens which play a 
significant role in the respiratory disease complex are O. rhinotracheale and E. coli.  
To treat respiratory infections in turkeys, drinking water treatment with enrofloxacin is 
widely used. The current treatment regimen advises a five day treatment at 10 mg/kg body 
weight. Although this labelled dosage proves very efficacious, the regimen is regarded as 
cumbersome for many farmers, since the medicated drinking water has to be prepared freshly 
every day for five days. Besides, in vivo emergence of diminished susceptibility or even 
resistance to fluoroquinolones is commonly encountered in many bacterial species from 
poultry. Several dosage strategies have been developed for the fluoroquinolone antimicrobials 
which may increase their efficacy and may reduce the selection pressure for resistance. 
Nevertheless, controlled clinical studies which address their efficacy against O. 
rhinotracheale and Escherichia coli infection have not been reported.  
 
The general introduction starts with a survey on the characteristics of enrofloxacin. 
The relationship between its structure and activity, the physicochemical properties of the 
molecule, the mechanism of enrofloxacin action, its pharmacokinetic and pharmacodynamic 
parameters, related toxic effects and drug interactions, aspects of fluoroquinolone resistance 
and dosing strategies are the themes that have been reviewed.  
Next a review of the literature is given on O. rhinotracheale infections in turkeys. Properties 
described are the general characteristics of O. rhinotracheale, the pathogenesis, 
epidemiology, clinical signs and lesions, diagnosis, preventive measures and treatment.  The 
last part of the general introduction deals with APEC infections in turkeys. The briefy 
reviewed are the aspects of respiratory colibacillosis in turkeys, the virulence associated 
factors and diagnosis, treatment and prevention of APEC infections.  
 
The scientific aim of this research was to optimize enrofloxacin dosage regimens 
against respiratory disease caused by avian metapneumovirus (APV)/O. rhinotracheale and 
APV/E. coli infections in turkeys by modifying the duration of the treatments and/or the daily 
administered enrofloxacin concentrations. 
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In a first experimental study, three single day enrofloxacin treatment regimens 
providing 50 mg/kg body weight during a 5, 10 or 20 hour period were compared to the 
advised multiple day treatment regimen with 10 mg/kg body weight for 5 successive days in 
turkeys experimentally inoculated with APV and O. rhinotracheale. Although initially all 
dosage regimens cleared O. rhinotracheale from the trachea, four days after onset of 
treatment, O. rhinotracheale bacteria were re-excreted in the single day regimens but without 
clinical relapse. The five day treatment with 10 mg enrofloxacin/kg in turkeys provided the 
best results for the treatment of an O. rhinotracheale infection in growing turkeys by 
shortening the course and reducing the severity of clinical disease and by eliminating O. 
rhinotracheale from the respiratory tract without re-emergence. None of the treatment 
regimens promoted the selection of bacterial clones with reduced susceptibility or resistance. 
In a second study, it was assessed whether a single day treatment schedule with 50 
mg/kg body weight was clinically equivalent to the advised multiple day treatment schedule 
with 10 mg/kg body weight for five days against turkeys experimentally inoculated with APV 
and three days later with E. coli. Both the multiple and the single day enrofloxacin treatment 
regimens reduced E. coli multiplication in the respiratory tract tissues (turbinates, trachea and 
lung) but the five day treatment with 10 mg enrofloxacin/kg in turkeys provided the best 
results by shortening the course of clinical disease, by eliminating E. coli from the respiratory 
tract without re-emergence, and by reducing macroscopic lesions. None of the treatment 
regimens promoted the selection of bacterial clones with reduced susceptibility or resistance. 
A third experimental study was a dose titration study. Growing turkeys were first 
infected with APV and three days later with O. rhinotracheale. Twenty four h after O. 
rhinotracheale inoculation, enrofloxacin doses of 5, 10 or 20 mg/kg body weight were 
administered for 5 successive days. All enrofloxacin treatments were equally efficacious, i.e. 
equally capable of shortening the course of clinical disease, eliminating O. rhinotracheale 
from the respiratory tract and reducing gross lesions. None of the used treatment regimens 
promoted the selection of bacterial clones with reduced susceptibility or resistance to 
enrofloxacin.  
Finally, a reduced duration medication study was performed. To evaluate the current 
enrofloxacin treatment schedule in growing turkeys experimentally infected with APV and O. 
rhinotracheale, the following enrofloxacin regimens providing the same total administered 
dose (50 mg / kg BW) were compared: 25 mg / kg BW / day on day 0 and day 2 or15 mg / kg 
BW / day on days 0, 2 and 4 and 10 mg / kg BW for 5 successive days. Again, all 
enrofloxacin treatments proved equally efficacious, i.e. equally capable of shortening the 
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course of clinical disease, eliminating O. rhinotracheale from the respiratory tract and 
reducing gross lesions. None of the used treatment regimens promoted the selection of 
bacterial clones with reduced susceptibility or resistance to enrofloxacin. 
 
Based on the results in the experimental studies performed during this research, the 
current labelled treatment regimen proved very efficacious against respiratory disease caused 
by susceptible O. rhinotracheale and E. coli strains. The efficacy of the single day treatments 
against O. rhinotracheale and E. coli infections did not equal that of the five day treatment, 
possibly by not eliminating the respiratory pathogens from the organs, which made it possible 
for the remaining bacteria to re-emerge. The regimens tested during the dose titration and 
reduced duration studies proved equally effective against susceptible O. rhinotracheale 
infections. Therefore, depending on the evolution of the respiratory disease in the stable, a 
flexible adaptation of the duration of enrofloxacin drinking water treatment is possible. The 
reduced duration applications providing 2 times 25 mg/kg or 3 times 15 mg/kg enrofloxacin, 
alternated each time by a day without treatment, could offer less time-consuming and equally 
effective alternatives to the currently labelled treatment against O. rhinotracheale infections 
in turkeys. Neither the current labelled dosage nor any modified regimen ever promoted the 
selection of less susceptible or resistant isolates. 
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SAMENVATTING 
 
In de kalkoenindustrie zijn luchtweginfecties wereldwijd een vaak voorkomend 
probleem met zware economische verliezen als gevolg. De verliezen zijn voornamelijk te 
wijten aan verhoogde voederconversie, vermindere groei, verhoogde sterftepercentages, een 
hoger aantal karkasafkeuringen bij verwerking en hogere medicatie kosten. Twee bacteriële 
ziektekiemen die vaak geassocieerd worden met ademhalingsproblemen bij kalkoenen zijn 
Ornithobacterium rhinotracheale en Escherichia coli. 
Enrofloxacine is een antimicrobieel product, behorend tot de klasse van de fluoroquinolones, 
dat vaak wordt voorgeschreven ter behandeling van zulke ademhalingsinfecties in kalkoenen. 
Het huidig behandelingsschema adviseert een dosis van 10 mg enrofloxacine/kg 
lichaamsgewicht, toe te dienen via het drinkwater gedurende 5 opeenvolgende dagen (label 
dosering). Ondanks zijn bewezen doeltreffendheid, vinden veel kalkoenhouders dit 
behandelingsschema omslachtig omdat het gemedicineerd drinkwater elke dag -vijf dagen 
lang- opnieuw moet worden aangemaakt. Ook worden er in vivo uit pluimvee regelmatig 
bacteriën geïsoleerd die een verminderde gevoeligheid of zelfs resistentie tegenover 
fluoroquinolones  vertonen. Recent zijn er echter verscheidene dosisstrategieën ontwikkeld 
die de werkzaamheid van deze klasse  antimicrobiële middelen zouden kunnen verhogen en 
daarnaast de selectie van resistente kiemen zouden verminderen. De efficaciteit van deze 
strategieën zijn echter nog nooit uitgetest op O. rhinotracheale en E. coli infecties.  
  
In de algemene introductie van dit werk wordt eerst enrofloxacine onder de loep 
genomen. De structuur, de fysicochemische eigenschappen, het werkingsmechanisme van de 
molecule, de farmacodynamische en farmacokinetische eigenschappen, de toxische effecten, 
de interacties met andere preparaten, resistentievorming en de ontwikkelde dosisstrategieën 
van het antimicrobieel product worden besproken. 
Vervolgens wordt er een literatuuroverzicht gegeven over O. rhinotracheale infecties in 
kalkoenen. De algemene kenmerken, de pathogenese, de epidemiologie, klinische symptomen 
en klinische letsels, diagnose, de behandeling van O. rhinotracheale infecties en preventieve 
maatregelen komen aan bod. Tenslotte volgt er een stukje over Aviaire Pathogenische E. coli 
(APEC) infecties in kalkoenen, met daarin de volgende onderwerpen: respiratoire 
colibacillose, de geassocieerde virulentie factoren en de diagnose, de behandeling en de 
preventie van APEC infecties. 
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Het doel van dit onderzoek was om het huidige behandelingsschema van enrofloxacin 
dat gebruikt wordt ter behandeling van APV/O. rhinotracheale and APV/E.coli infecties te 
optimaliseren door de behandelingsduur en/of de dagelijks toegediende dosis van 
enrofloxacine aan te passen.  
 
In een eerste studie werd de efficaciteit van eendaagse enrofloxacine behandelingen 
vergeleken met die van het huidig geregistreerde meerdaagse behandelingsschema. Na 
inoculatie met  APV en O. rhinotracheale werden drie groepen kalkoenen gedurende 5, 10 of 
20 u behandeld met een dosis van 50 mg enrofloxacine/kg lichaamsgewicht. Een vierde groep 
kreeg gedurende 5 opeenvolgende dagen 10 mg/kg enrofloxacine toegediend. Alle 
behandelingen slaagden erin O. rhinotracheale uit de trachea te verwijderen, maar enkele 
dagen na start van de medicatie werd na de eendags-therapieën O. rhinotracheale opnieuw in 
de trachea aangetroffen. Van de vier behandelingen, slaagde de huidig geregistreerde 
behandeling er het beste in het ziekteverloop in te korten en het ziektebeeld te verzachten 
zonder re-excretie van O. rhinotracheale. Tijdens de studie werden geen O. rhinotracheale 
isolaten geïsoleerd met verminderde gevoeligheid of resistentieontwikkeling tegenover 
enrofloxacine. 
In een tweede studie werd onderzocht of één dag behandelen aan een dosis van 50 mg 
enrofloxacine/kg lichaamsgewicht even werkzaam is als de huidig geregistreerde behandeling 
van 10 mg enrofloxacine/kg gedurende 5 opeenvolgende dagen voor de behandeling van 
APV/E. coli infecties in kalkoenen. Beide behandelingen reduceerden de E. coli 
vermenigvuldiging in de luchtwegen, maar de geregistreerde behandeling slaagde er het best 
in E. coli uit de kalkoenen te elimineren, de ziekteduur te verkorten, en de symptomen en 
letsels te beperken. Tijdens de studie werden geen O. rhinotracheale isolaten geïsoleerd met 
verminderde gevoeligheid of resistentieontwikkeling tegenover enrofloxacine. 
Vervolgens werd een dosis-titratie studie uitgevoerd. Na inoculatie met APV en O. 
rhinotracheale werden kalkoenen 5 dagen na elkaar behandeld met 5, 10 of 20 mg 
enrofloxacine/kg lichaamsgewicht/dag. Alle behandelingen bleken even effectief in het 
elimineren van O. rhinotracheale uit de luchtwegen, het verkorten van de ziekteduur, en het 
verminderen van klinische symptomen en letsels. Tijdens de studie werden geen O. 
rhinotracheale isolaten geïsoleerd met verminderde gevoeligheid of resistentieontwikkeling 
tegenover enrofloxacine. 
Tenslotte werd een studie uitgevoerd waarin het huidige geregistreerde 
behandelingsschema van enrofloxacine (10 mg/kg gedurende 5 opeenvolgende dagen) werd 
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vergeleken met therapieën waarbij op alternerende dagen werd behandeld met behoud van de 
totale dosis: 25 mg/kg/dag op dag 0 en dag 2 of 15 mg/kg/dag op dag 0, 2 en 4. Ook in deze 
studie bleken alle behandelingen even effectief in het elimineren van O. rhinotracheale uit de 
luchtwegen, het verkorten van de ziekteduur, en het verminderen van klinische symptomen en 
letsels. Tijdens de studie werden geen O. rhinotracheale isolaten geïsoleerd met verminderde 
gevoeligheid of resistentieontwikkeling tegenover enrofloxacine. 
 
Uit de resultaten van de uitgevoerde experimenten kunnen we besluiten dat het huidige 
geregistreerde behandelingschema  van enrofloxacine (10 mg/kg gedurende 5 opeenvolgende 
dagen) zeer effectief is tegen ademhalingsinfecties veroorzaakt door APV/O. rhinotracheale 
en APV/E. coli. Behandelingsschema’s waarin de totale enrofloxacine dosis (50 mg) in 
éénzelfde dag wordt toegediend bleken geen goed alternatief, aangezien zowel O. 
rhinotracheale als E. coli niet volledig werden geëlimieerd en na enkele dagen opnieuw 
konden vermenigvuldigen in de luchtwegen van de kalkoenen. De behandelingsschema’s die 
werden getest tijdens de dosis titratiestudies en de medicaties waarbij op alternerende dagen 
werd behandeld bleken even effectief als het huidig geregistreerde regime. Dit wijst erop dat, 
afhankelijk van het verloop van de ziekte in de stal, drinkwater therapie met enrofloxacine 
flexibel kan worden aangepast. Bovendien leveren de therapieën waarbij 2 keer 25 mg/kg of 3 
keer 15 mg/kg enrofloxacine wordt toegediend een waardevol alternatief voor het 
geregistreerde regime, aangezien maar 2 of 3 dagen moet behandeld worden in plaats van 5. 
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Haesebrouck bedankt om mij de kans te geven te mogen starten aan de dienst bacteriologie. 
Ook voor het steeds  kritische nalezen van al mijn geschreven werk. 
 
Dit project werd mogelijk gemaakt met de financiële steun van Bayer Healthcare 
GmbH. Daarom ook aan hen mijn dankbetuigingen.  
Robrecht Froyman was de eerst twee jaar van mijn onderzoek de vertegenwoordiger 
van de firma. Alvorens onze eerste ontmoeting had Maja mij gewaarschuwd dat je een streng 
voorkomen had, maar dat schijn bedriegt…en dat is dan ook gebleken. In het begin hadden 
we het een beetje lastig met de administratieve toepassingen van de GCP guidelines, maar 
uiteindelijk hebben we QM toch tevreden kunnen stellen. Dank je voor je input, je 
correctheid, je hulp en kritisch nalezen van mijn artikelen. In mijn laatste jaar werd jouw taak 
overgenomen door Dr. Carolin Ludwig. Carolin, bedankt voor de leuke samenwerking, je 
blijk van appreciatie voor mijn werk en de leuke persoonlijke toetsen in je e-mails. Moest je 
nog eens in Gent terecht komen, ben ik altijd bereid om eens persoonlijk gids te spelen in 
plaats van tips op papier te geven. 
Ook mag ik zeker Luc Jansegers niet vergeten. Aangezien mijn experimenten 
verliepen volgens GCP condities moest er een monitor worden aangesteld. Toen ik dit hoorde, 
dacht ik: “Oh nee, ene die constant op mijn vingers komt zien!” Maar achteraf bleek dat 
allemaal goed mee te vallen. Je bent een joviale man. Ik heb deze drie jaar graag met je 
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samengewerkt en ook jij bedankt voor je kritische input tijdens het schrijven van de vele 
protocols en study reports. 
 
Speciaal wil ik mijn projectvoorgangster bedanken, Dr. Maja Marien. Hoewel je al bij 
Alpharma aan de slag was, heb je toch nog tijd weten uit te trekken om mij wegwijs te maken 
in het labo en de praktische zaken van dit onderzoek en later kon ik steeds met mijn 
praktische vragen bij jou terecht. Ook je achtergelaten documentatiemappen zijn voor mij van 
onschatbare waarde geweest. 
 
Voor publicatie werd dit proefschrift nagelezen door mijn begeleidingscommissie, 
bestaande uit Dr. R. Froyman en Prof. Dr. H. Nauwynck en de leden van de 
examencommissie, zijnde Prof. Dr. F. Gasthuys, Prof. Dr. L. De Zutter, Prof. Dr. P. De 
Backer, Prof. Dr. L. Duchateau en Dr. M. Marien. Dank, voor jullie tijd en kritische 
opmerkingen. 
 
In vivo proeven zijn hard labeur en aangezien ik als enige aangesteld was op dit 
project, had ik vaak hulp nodig van helpende handen. Hulp die ik vanuit verschillende hoeken 
met veel bereidwilligheid heb gekregen. Ik denk dat de meesten wel eens een handje hebben 
toegestoken -iedereen bedankt daarvoor!- maar ik wil toch mijn speciale appreciatie uiten aan 
Ellen Dewaele, Marleen Foubert en Veerle Flama voor het vele helpen bij het swabben en 
uitvoeren van de autopsies en aan mijn dispensers Nathalie Van Rysselberghe en Sofie De 
Bruyckere.  
 
Een universitaire werkplek is altijd een beetje een komen en gaan van mensen. Tijdens 
mijn onderzoeksperiode heb ik dan ook met verschillende mensen “den bureau” gedeeld. Bij 
mijn start zat ik bij Liesbeth en Hilde. Dr. Liesbeth vertrok naar Janssens en Hilde ging op 
zwangerschapsverlof. Lieven nam even de leeggekomen plek in tot Hildes terugkeer. Dr. 
Hilde vertrok naar Alcon en David verscheen in de plaats samen met Melanie, toen nog 
laatstejaarsstudente. En dan hadden we ook nog de buitenlandse gasten: Bill de Griek en 
Vietnamese Dung. Met al mijn bureaugenootjes heb ik goed kunnen opschieten en ik denk zij 
ook wel met mij. Bedankt voor de leuke tijd samen! 
De dienst bacteriologie is een leuke werkplek, waar tussen het serieuze werken door 
ten gepaste tijde plezier kan worden gemaakt. Daarom ook aan al de andere collega’s van de 
bacterio en pluimvee van nu en weleer: Tom, Lies, Lieve, Urszula, Sandrine, Jo, Gunter, 
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Katleen, Marc, Kim, Anouk, Leen, Miet, Venessa, Sofie, Renzo, Filip, Koen, Annemieke, 
Pascale, Els, Dries, Kathleen, Jana, Elin, Bram, Alexander, Hanne, Anja, Serge, Arlette, 
Rosalie, Roseline, Ruth en Sofie.  Bedankt voor jullie collegialiteit en vriendschap. (BTW, 
moest ik iemand in het lijstje vergeten zijn…mijn oprechte verontschuldigingen hiervoor! Het 
was niet express, maar we zijn dan ook met zoveel!)    
Ook nog een bedankinkje aan enkele mensen van de dienst virologie. Aan Carine, om 
mij in te werken in de trachearingetjes en virustitraties. En ook aan Fernand en Geert om erin 
te slagen de rotor, ondanks zijn vergevorderde leeftijd, te laten blijven draaien en ook te 
helpen bij de installatie van de isolatoren tijdens mijn eerste dierproef.    
Ook mijn appreciatie aan Magda. Bedankt voor al het werk dat je verzet in de stallen. 
  
Meteen neem ik deze gelegenheid ter harte om eens mijn vrienden en familie te bedanken, om 
te zijn wie ze zijn. 
Aan “the girls”: meisjes, als wij uitgaan is het nooit saai! Dank jullie voor de vele 
leute, zowel met als zonder drama, die we al beleefd hebben en hopelijk nog vaak zullen 
beleven. Met Bregje kreeg ik er ineens ook een boel andere vriendjes bij. Allez, het is te 
zeggen vriendinnetjes en Jef. Windeke clan, ook jullie bedankt voor de vele leuke momenten 
die we al beleefd hebben. 
Papa, jij en mama hebben ons altijd de vrijheid gegeven om zelf onze weg te kiezen in 
het leven en in de keuzes die we maakten werden we altijd gesteund. We werden niet 
betutteld, maar we hebben nooit iets tekort gehad en als er iets was stonden jullie en sta je nog 
altijd klaar voor ons. Dank je hiervoor. De voorbije jaren zijn niet altijd even gemakkelijk 
voor je geweest, maar tegenwoordig is er weer een lichtpunt in je leven. Je straalt en dat gun 
ik je van harte. Mappi, bedankt om papa weer te laten stralen.  
Mama, ik mis je nog steeds elke dag. Er zijn zo van die speciale momenten in iemands 
leven die je graag wilt delen met de mensen die je graag ziet. Op zulke momenten, zoals 
vandaag, mis ik je des te meer. Bedankt voor alles wat je ooit voor me gedaan hebt en ooit 
zien we elkaar weer.      
Broertjes en zusje, het spreekwoord zegt: “Uw vrienden kun je kiezen, uw familie 
niet”. Moest ik kunnen kiezen, ik zou jullie voor geen geld van de wereld willen inruilen. 
Weet dat jullie altijd op mij kunnen rekenen! Schoonzusjes en schoonbroertje, kindjes, jullie 
zie ik ook allemaal graag. 
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Chris en Theo, vanaf onze eerste ontmoeting ben ik door jullie steeds warm onthaald 
geweest. Dank voor jullie gastvrijheid, liefde en steun. Ook Lemke, Simon en kleine Arend, 
bedankt voor de vriendschap. 
 
Bregje, mijn liefste schatje. De reden dat ik hier vandaag op deze plek sta is 
grotendeels te danken aan jou. Moest jij er niet geweest zijn, stond ik nu waarschijnlijk ergens 
pinten te tappen aan één of andere toog, ofzo…. Ik hou van jou, oprechter elke dag, versteld 
van het zalige gevoel dat je me geeft telkens weer als we bij elkaar zijn.  Bedankt voor je 
steun, je liefde en om er steeds weer te zijn voor mij…elke dag opnieuw. Je bent mijn alles. 
 
  
 
